Adaptive vaccination may be needed to extirpate COVID-19:

Results from a runtime-alterable strain-drift and waning-immunity model

Wayne M. Getz^{1,2,3}, Richard Salter^{3,4}, Ludovica Luisa Vissat¹, James S. Koopman⁵, Carl P. Simon⁶

¹Dept. ESPM, UC Berkeley, CA 94720-3114, USA

²School of Mathematical Sciences, University of KwaZulu-Natal, South Africa

³Numerus, 850 Iron Point Rd., Folsom, CA 95630, USA

 $^4\mathrm{Computer}$ Science Dept., Oberlin
 College, Oberlin, Ohio, OH 44074, USA

⁵School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA

 $^6\mathrm{Gerald}$ R. Ford School of Public Policy, University of Michigan, Ann Arbor, MI 48109, USA

Corresponding Author: Wayne M. Getz, wgetz@berkeley.edu

Author Contributions: JSK and CPS initiated the project, provided feedback on early drafts and participated in discussions. WMG designed and formulated the SEIVD-IBM model, drafted the manuscript, ran simulations, and produced the figures. RS designed and built the J-RAMP platform and wrote the code and informational text. LLV checked all the mathematical equations and code. Both RS and LLV contributed to the structure of the manuscript. All authors contributed to editing and adding text as needed.

Competing Interest Statements: none

Classification. Major: Biological Sciences; Minor: Biophysics and Computational Biology

Keywords: SARS-CoV-2, SEIR models, multivalent vaccines, escape mutations, strain/variant proliferation

¹ Abstract

We developed an elaborated susceptible-infected-recovered (SIR) individual-2 based model (IBM) with pathogen strain drift, waning and cross immunity, implemented as a novel Java Runtime-Alterable-Model Platform (J-RAMP). This platform allows parameter values, process formulations, and scriptable runtime drivers to be easily added at the start of simulation. It includes facility for integration into the R statistical and other data analysis platforms. We selected a set of parameter values and process descriptions relevant to the current COVID-19 pandemic. These include pathogen-specific shedding, environmental persistence, host transmission and mortality, within-host pathogen mutation 10 and replication, adaptive social distancing, and time dependent vaccine rate and 11 strain valency specifications. Our simulations illustrate that if waning immu-12 nity outpaces vaccination rates, then vaccination rollouts may fail to contain the 13 most transmissible strains. Our study highlights the need for adaptive vaccina-14 tion rollouts, which depend on reliable real-time monitoring and surveillance of 15 strain proliferation and reinfection data needed to ensure that vaccines target 16 emerging strains and constrain escape mutations. Together with such data, our 17 platform has the potential to inform the design of vaccination programs that 18 extirpate rather than exacerbate local outbreaks. Finally, our RAMP concept 19 promotes the development of highly flexible models that can be easily shared 20 among researchers and policymakers not only addressing healthcare crises, but 21 other types of environmental crises as well. 22

23

Significance Statement: Effective COVID-19 vaccine development has been 24 unprecedented, but vaccinations are being delivered at contrasting rates across 25 the globe. Here, using an innovative epidemiological Java runtime alterable 26 modeling platform (J-RAMP), we demonstrate that seemingly reasonable vac-27 cination programs may exacerbate rather than mitigate regional outbreaks when 28 immune waning outpaces vaccinations and reinfection promotes escape muta-29 tions. Our simulations suggest that adaptive vaccination programs, requiring 30 adequate strain and serology monitoring and surveillance, are needed to extir-31 pate outbreaks. Our platform provides policymakers with an easy-to-use tool 32 for designing effective vaccination programs. Our RAMP concept points the 33 way to the development of highly flexible models that are easily shared among 34 researchers and policymakers in all areas of systems analysis. 35

Submitted to PNAS

36 Introduction

Vaccines have either eliminated, or all but eliminated, diptheria, measles, po-37 lio, rubella, small pox, and tetanus within developed countries, such as the 38 USA [1]. The global COVID-19 pandemic has amply illustrated the overwhelm-39 ing economic importance that vaccines can play in bringing an epidemic un-40 der control [2]. Unlike the above mentioned diseases and more inline with in-41 fluenza, however, the SARS-CoV-2 pathogen may re-emerge with vengeance 42 due both to waning immunity and proliferation of mutant strains or variants 43 with increased transmissibility that escape both naturally-acquired and vaccine-44 induced immunity [3–8]. To investigate how effective vaccination programs may 45 be in preventing future large-scale outbreaks of COVID-19 [9, 10], we built a 46 Java Runtime-Alterable-Model Platform (J-RAMP) of an SEIVD (Susceptible, 47 Exposed, Infectious, V=Immune & Vaccinated, Dead) individual-based model 48 (IBM) [11–14] that includes the following processes (Fig. 1; see Materials and 49 Methods, as well as Appendix A for details): 50

pathogen strain-specific shedding [15], environmental persistence [16], with host replication [17] and mortality rates [18] (some prefer the term variant
 rather than strain)

- immunological waning with strain cross immunity [6,19]
- pathogen strain drift during transmission and within-host replication [20]
 - an adaptive contact rate [21]

54

56

• a time-dependent, uni- or multivalent vaccine rollout [22,23]

Our SEIVD-IBM J-RAMP, is an example of our novel runtime alterable-model 58 platform (RAMP) concept, which includes panels, windows and sliders that al-59 low users to specify and manipulate model parameter values in real time, as well 60 as modify process function descriptions, even during the course of a simulation, 61 while protecting the integrity of the underlying code. Thus our SEIVD-IBM 62 J-RAMP has epidemiological applications well beyond COVID-19, including 63 diseases such as influenza [24], Ebola [25, 26], and any other directly transmit-64 ted disease [27]. To illustrate its application, we used our J-RAMP to explore 65 the relative efficacy of uni- and multivalent vaccines applied at various time-66 dependent rates, where choice of valency may switch in response to realtime 67 monitoring and surveillance data. Such adaptive vaccination programs may be 68 required to combat the evolutionary arms race between vaccine efficacy and the 69 evolution of new pathogen strains [20,23,28]. We demonstrate the possible con-70 sequences of vaccinating too few individuals in the context of the emergence of 71 more transmissible strains, as well as the comparative efficacy of non-adapative 72 versus adaptive vaccines responsive in realtime to current strain valency. We 73 simulate plausible COVID-19 outbreaks over a three year period in which vac-74 cination rollout commences at the start of year two and continues until the end 75 of the year three. 76

Our study is meant to highlight issues related to vaccination rollout rates [10] and strain valency that may turn out to provide insufficient coverage of the population or being outrun by waning immunity in vaccinated hosts or those that have survived COVID-19. We undertake these simulation with the knowledge that though a typical set of parameters may cover most outbreaks of COVID-19

Submitted to PNAS

in various regions around the world, regional differences in the contact behavior 82 of individuals, with additional contact rate time dependency in each locality 83 due to social distancing regulations and behavior, have led to markedly differ-84 ent outbreak patterns across regions [29–31]. Thus the result presented here are 85 meant to inform us of potential pitfalls and dangers in rolling out inadequate 86 vaccination programs and extract general principles, where possible, as well as 87 illustrate an approach to its local application rather than prescribe a universal 88 program: adaptive programs need to operate in response to local surveillance 89 data and contact rate conditions. 90

91 The local nature of contact rate patterns is well established as an important driver of outbreak patterns [30]. The definition of a contact where transmission 92 may occur is rather challenging though. Effective or "close" contact may be 93 defined, as in [32], in terms of direct physical contact or close conversation, or it 94 may involve concepts of a threshold distance and time period [33]. Taken a step 95 further, it may relate to infectious dose levels and the relationship between dose 96 and severity of the infection of individuals [34]. This effective contact rate issue, 97 however, is side-stepped by fitting models to local incidence data to obtain a 98 concatenated contact-and-transmission rate parameter value that best fits local 99 outbreak patterns, as discussed in depth elsewhere [30]. 100

Our results also suggest that adaptive vaccination programs that closely 101 monitor the emergence of new strains and adapt vaccine valency to match pre-102 dominating strains are much more likely to extirpate local epidemics than non-103 adaptive policies, though our simulation results are greatly influenced by as-104 sumptions regarding rates of waning immunity and strain cross-immunity char-105 acteristics as well. Accurate forecasting of the future course of an epidemic in 106 terms of strain composition and vaccination program efficacy require data on 107 the rates at which immunity wanes, how such immunity depends on particu-108 lar strains, and the levels of cross immunity among strains [4, 6] that are more 109 comprehensive than currently available. It also requires better data on within-110 host replication and mutation rates. Thus, in truth, we present our model 111 and results fully aware that answers to questions relating the design of optimal 112 region-specific vaccination programs await more reliable data on immunity pro-113 cesses, strain mutation rates [35], and the transmission potential and virulence 114 of dominant strains [36]. We hope, however, that our results and subsequent 115 investigations using our model provide the kinds of quantitative analyses that 116 can help formulate highly effective local or country level vaccination programs 117 that avoid many of the pitfalls revealed by our analysis, as well as encourage 118 the adoption of rapidly adaptive vaccination programs. 119

$_{120}$ Results

¹²¹ Single strain simulations

¹²² Our first simulation, which we regard as a "baseline run" has J = 0 (i.e., ¹²³ only one strain is possible), assumes a constant contact rate ($\kappa(t) = \kappa_0$ for all t; ¹²⁴ which implies no social distancing or effective contact reducing actions taken) in ¹²⁵ an a homogeneously, well-mixed population of ten thousand individuals ($N_0 =$ ¹²⁶ 10,000), with an immune waning half-life of one year ($t^{\text{half}} = 365$), and no ¹²⁷ vaccination rollout. The resulting simulation depicts a classic outbreak pattern

Getz et al., June 7, 2021

128

129

130

131

132

133

134

135

136

(Fig. 2) in which incidence rises to a peak of about 250 cases around 96 days after "patient zero" has been introduced, and then burns out around day 166 days because an insufficient number of susceptible individuals are now available to keep the epidemic going. In the upper left-hand panel of our SEIVD-IBM J-RAMP dashboard in Fig. 2, we see that around 3/4 of individuals have been infected at the point where the epidemic burns out (V(166) = 7700, which is 77% of N_0): this suggests that herd immunity may well be in the ball park of 75-80% (as supported by additional runs presented next), although this would

be an underestimate if more transmissible strains come to prevail.

137 Repeated runs of this first simulation with different runtime seeds (viz., 10) runs with runtime seeds ranging from 0 to, where each seed generates its own, 138 essentially unique, but repeatedly sequence of pseudo random numbers; Fig. 2 139 is for the case runtime seed = 0) produces the following means and standard 140 deviations as a percentage of the population size (of S, V and D), as well as the 141 length of the epidemic (days) (see Fig. C.1, Appendix C): $S_{\rm fnl} = 21.9 \pm 0.6\%$, 142 $V_{\rm fnl} = 76.4 \pm 0.6\%$, $D_{\rm fnl} = 1.6 \pm 0.1\%$, and $t_{\rm fnl} = 167 \pm 9$ days. These results 143 are almost the same when the initial population size is increased threefold to 144 $N_0 = 30,000$ individuals, the primary difference being a small expected decrease 145 in variability (around $1/3^{rd}$ smaller) and slightly longer epidemic period (18%) 146 longer) (see Fig. C.1 for details). To obtain full plots of the incidence, prevalence. 147 and daily-death trajectories from many runs of our SEIV-IBM, we exploited 148 the R-platform integrability of our J-RAMP to generate mean and standard 149 deviation plots of incidence, prevalence, and daily mortality, as described in 150 Appendix **B** (and Fig. C.2). 151

Our second single-strain (J = 0) simulation (Fig. 3A) illustrates that, for the 152 selected set of parameter values, if the rate of waning is tripled from that of our 153 first (i.e., t^{half} is reduced from 365 days to 120 days) then herd immunity is still 154 reached. Our third single strain simulation, however, shows that herd immunity 155 is eluded for the selected set of parameter values when this rate is quadrupled 156 $(t^{\text{half}} = 90 \text{ days}; \text{Fig. 3B})$: viz., the population enters a periodic outbreak mode 157 because previously infected individuals are sufficiently susceptible after several 158 months post-initial infection to be reinfected and thus keep the epidemic going. 159 Herd immunity in this caricatured population (i.e., relatively small, isolated, 160 homogeneous) would also be reached within a year if the waning immunity 161 half-life is increased back to $t^{half} = 180$, but not if an adaptive contact rate 162 is in operation (Fig. 3C & D; k(t) specified by Eq. A.10). More specifically, 163 for the case $p_{\rm T}^{\rm half} = 0.05$, that is the "effective" contact rate $\kappa(t)$ drops from 164 $\kappa(t) = \kappa_0 = 4$ when $I/N_0 = 0$ to $\kappa(t) = \kappa_0/2 = 2$ when I(t)/N(t) = 0.05, our 165 fourth single strain simulation indicates that prevalence peaks at roughly 400 166 individuals (i.e., just around 0.4% of the population) around day 85 (Fig. 3C), 167 drops to around 50 between days 210 and 240, and then rises back to over 168 200 by the end of one year. In our fifth single strain simulation (Fig. 3D), an 169 additional 5-fold reduction in our adaptive contact rate (i.e., $\kappa(t) = \kappa_0/2 = 2$ 170 when I(t)/N(t) = 0.01) produces a prevalence of just under 100/10,000=0.01% 171 that appears to persist with stochastic noise from day 100 onwards. 172

We carried out two additional single strain simulations, this time for three years, and applied a vaccination rollout program that vaccinated individuals drawn at random in the second and third year at rates v = 0.001 and v =

Submitted to PNAS

0.002 (0.1% and 0.2% of the population vaccinated each day; Fig. 4A & B), 176 respectively, from a pool consisting of individuals not currently infectious or 177 previously vaccinated. In these runs, we set $t^{\text{half}} = 365$ days, $p_{\text{T}}^{\text{half}} = 0.002$ 178 (reflecting US case percentages after 1 year), with a population size of $N_0 =$ 179 100,000. In the case v = 0.001, the vaccination rate was insufficient to overcome 180 the rate at which infected individuals were becoming reinfected due to waning 181 immunity. In the case v = 0.002, the vaccination rate was sufficiently high to 182 bring the epidemic under control. In the latter case, however, if we no longer 183 allow individuals who had previously been infected to be part of the vaccination 184 185 pool as well (i.e. we confine vaccinations to the \mathbf{S} class only), the vaccination rollout rate v = 0.002 is now insufficient to extinguish the outbreak and a 186 resurgence occurs around the end of the second year (Fig. 4C). 187

188 Multi-strain simulations

In all our multi-strain simulations we set $p_{\rm I}^{\rm half} = 0.005$. This latter value, as previously mentioned, produces a cumulative number of cases of around 10% in the first year in a population of size $N_0 = 100,000$ (Appendix C, Fig. C.3), which is in the ballpark of 8.5% for the US outbreak during its first year.

In our first set of multistrain simulations, we set J = 4 (i.e., permitting 16 strains) and compared the situations where cross immunity is absent (c = 0; Fig. 5A) to where it has the intermediate value c = 0.5 (Fig. 5B). The remaining parameters were the same for all strains and used the same basic epidemiological parameters, as in our previous single strain simulations, although mutation rates were now added to enable new strains to proliferate (see caption to Fig. 5 for details on parameter values).

In the no cross immunity (Fig. 5A) case, we see that the initial surge is 200 driven by strain $0 \equiv (0, 0, 0, 0)$ (see discussion in Appendix A for use of binary 201 representation), which is first replaced by strain $8 \equiv (1, 0, 0, 0)$ around the end 202 of year 1, which in turn is somewhat displaced by strains $7 \equiv (0, 1, 1, 1)$ and 203 $6 \equiv (0, 1, 1, 0)$, with strain $1 \equiv (0, 0, 0, 1)$ coming to dominate at the start of year 204 3, only to be finally challenged by strain $3 \equiv (0, 0, 1, 1)$ towards the end of year 205 3. In the nearest-neighbor cross immunity case (Fig. 5B), given the retarding 206 effect of cross immunity on the proliferation of strains that differ in only one 207 allele from the initial dominating strain $0 \equiv (0, 0, 0, 0)$, this initial strain was 208 displaced by strains $3 \equiv (0, 0, 1, 1)$ and $11 \equiv (1, 0, 1, 1)$ around the end of year 209 1. These latter 2 strains were then displaced by strain $7 \equiv (0, 1, 1, 0)$ during the 210 first half of year 3, with strain $13 \equiv (1, 1, 0, 1)$ dominating at the end of year 3 211 somewhat supported at a lower level by strain $14 \equiv (1, 1, 1, 0)$. We also noticed 212 a moderate resurgence of strain $0 \equiv (0, 0, 0, 0)$ in the middle of year 3. 213

In a second set of multistrain simulations, we set J = 7 for a total of 128 214 possible strains. Unlike the previous set of multistrain simulations, we now 215 provided a strain specific set of transmission parameters β_i by selecting these at 216 random on the interval [0, 0.3], apart from a dominant sequence of transmission 217 values that steps in increments of 0.25 from 0.3 in strain 0 to 0.475 in strain 218 127 along the sequence mentioned in the caption to Fig. 6 and documented 219 in Fig. C.4. The remaining parameters are the same as for the simulation 220 depicted in Fig. 5B (i.e., the cross-immunity parameter c = 0.5). Unlike the 221

case, J = 4, only two strains now played any serious role in the outbreak in the non-vaccination scenario (Fig. 6A): strain $0 \equiv (0, 0, 0, 0, 0, 0, 0)$ for the first year and strain $127 \equiv (1, 1, 1, 1, 1, 1)$, the most transmissible, for the remaining 2 years.

226 Vaccination rollout simulations

Following our no-vaccination simulation of our 128-strain case (Case A; Fig. 6A), 227 we explored three different vaccination rollout programs applied in years 2 and 228 3 with the following vaccination rates and vaccine strain valencies: Case B, rate 229 v = 0.002 (i.e., 0.2% vaccinated per day), strain valency 0 (Fig. 6B); Case C, rate 230 v = 0.002, strain valency 127 (Fig. 6C); and Case D, v = 0.01, strain valency 231 (0,7,31,127) (Fig. 6D). Each of these vaccination programs begin with the initial 232 strain $0 \equiv (0, 0, 0, 0, 0, 0, 0)$ being replaced by strain $127 \equiv (1, 1, 1, 1, 1, 1, 1)$ 233 towards the end of year 1 or start of year 2. 234

Alarmingly, the first vaccination rollout scenario (Case B) made the epi-235 demic worse rather than better when compared with the no vaccination scenario 236 (number of deaths were 1366 versus 1122; compare Figs. 6A and B) because the 237 vaccination rollout with its strain 0 valence vaccine, though delaying the emer-238 gence of strain 127, led to an increased prevalence of this most transmissible 239 strain ($\beta_{127} = 0.475$ versus $\beta_0 = 0.300$). Using a strain 127 valence vacci-240 nation (Case C) had some effect in reducing the 3-year death total back to 241 1109, but the efficacy of this rollout was thwarted by the emergence of strain 242 $48 \equiv (0, 1, 1, 0, 0, 0, 0) \ (\beta_{48} = 0.295, \text{ Fig. 6C}).$ 243

Given the inability of these two monovalent vaccination rollout programs in 244 years 2 and 3 to control the outbreak, we simulated the much more aggressive 245 rollout program of a quadravalent (0,7,31,127) vaccine applied at a rate of 1% per 246 day (v = 0.01; a five-fold increase over the previous two monovalent programs) 247 in a system with increased levels of cross immunity (cascading versus simple) 248 and including revaccination of previously vaccinated individuals to combat the 249 effects of waning immunity. Even this aggressive vaccination rollout program 250 failed, although it did knock the incidence way down at the start of the rollout. 251 The efficacy of this rollout, however, was thwarted by the rise of strain $23 \equiv$ 252 (0, 0, 1, 0, 1, 1, 1) ($\beta_{23} = 0.214$) during the mid to latter part of the second year, 253 which was then supplanted by strain $3 \equiv (0, 0, 0, 0, 0, 1, 1)$ ($\beta_3 = 0.350$), which 254 dominated the third year (Fig. 6D). 255

Unsurprisingly, the success of any vaccination program depends on the rel-256 ative robustness of the immunity characteristics of hosts to the various strains. 257 Thus, in regard to the vaccination programs represented by cases **B** and **C** 258 (Fig. 6, we simulated the rollout of a bivalent vaccine with strain valency (0,127)) 259 implemented at the same vaccination rate of v = 0.002, but in a system with 260 much more robust immunity characteristics: a waning half-life increased from 261 $t^{\text{half}} = 365$ to 1825 days (a five-fold increase) and a cascading cross immunity 262 system with c increased from 0.5 to 0.9. In this case, the outbreak was rapidly 263 extirpated after 257 days (i.e., from start at day 365 to extirpation at day 622). 264 Given the failure of our first three 128 strain vaccination rollouts (cases **B** 265

to **D** in Fig. 6) to extirpate the simulated epidemics, we investigated whether rollout programs that adapted vaccine valencies to track in real time the emer-

Submitted to PNAS

gence of dominant strains might be more effective. Thus, we used a JS scripting 268 window to write a JavaScript driver (as described in Appendix B; see Fig. B.4) 269 that adapted (i.e., switched as necessary) the valency of the vaccine every 90 270 days after the start of the vaccination rollout to match the top two strains 271 prevalent at time of switching, or only the top strain if no other strain exceeded 272 a prevalence of 10 individuals. The results of these two simulations, one for the 273 nearest-neighbor cross-immunity case (Eq. 1) and one for the cascading cross-274 immunity case (Eq. A.7), are provided in Fig. 7. They should be compared 275 with the non-vaccination case depicted in Fig. 6A and the non adaptive vac-276 277 cination rollout depicted in Fig. 6D. In contrast with the latter—and despite having the same vaccination rates, the same strategies for selecting non-infected 278 individuals at random, and employing vaccines with fewer strain valency—both 279 of these adaptive vaccination rollouts extirpated the epidemic, the first within 280 half a year (Case A) and the second within 1.4 years (Case B) from the start of 281 vaccination rollout. 282

283 Discussion

The amount of structure and data needed in complex biological systems' mod-284 els, depends on the questions that these models have been formulated to ad-285 dress [26,37]. In this paper, we steered away from making specific predictions-286 because universal solutions are not always locally applicable. Rather, we focused 287 on questions relating to the potential efficacy of different vaccination rollouts 288 (both vaccination rates and valencies of vaccines) in the context of strain emer-289 gence and the potential for vaccination programs to go awry. To make specific 290 predictions requires localized data, particularly as it may relate to social dis-291 tancing behavior or other factors that affect contact rates over time [30, 38, 39]. 292 Additionally, we cannot expect models to make strain-specific informative pre-293 dictions, unless they have been designed to do so and are supported by location 294 specific data regarding the relative transmissibility of strains and other strain 295 specific data. In the absence of such data, models become a tool for anticipat-296 ing pitfalls and avoiding unintended consequences of well-intentioned actions. 297 Equally important, however, is the implementation of our model as a RAMP 298 (runtime alterable model platform), because this greatly facilitates the use of 299 our model by ourselves and others in testing out different hypothesis about the 300 process generating observed population level strain transmission dynamics. 301

The illustrative simulations we present demonstrate that if vaccination roll-302 out rates and vaccine valencies are applied in blanket manner—that is, without 303 monitoring strain emergence and obtaining some assessment of the epidemio-304 logical characteristics of those strains (e.g., relative transmissibility, virulence, 305 waning and cross immunity characteristics)—then the possibility exists for a 306 vaccination program to do more harm than good. This of course, is not to say 307 308 that vaccination programs should ever be avoided; only that once a vaccination program is embarked upon, it should be implemented at a sufficiently vigorous 309 rate to ensure that it is not outrun by relatively fast waning immunity rates. 310 Additionally, when escape mutations emerge, generally associated with reinfec-311 tion cases [8], then the valency of vaccines should be switched rapidly enough to 312

Submitted to PNAS

thwart escape mutations, rather than aiding such mutations by thwarting less transmissible competing strains instead.

At this time, the primary value of our SEIVD-IBM J-RAMP is in testing var-315 ious vaccination strategies as they relate to strain emergence [40] and identifying 316 pitfalls related to the unintended promotion of more transmissible or virulent 317 strains. Strain emergence has both a local and global component. Particu-318 lar strains may first be identified as occurring in specific geographical regions, 319 as in the strains that appear to have originated in the UK (B.1.7.7 variant), 320 South Africa (variants B.1.1.54, B.1.1.56 and the C.1 lineage) and Brazil (P.1 321 lineage) [41]. Thus more geographically focused application of our J-RAMP 322 may require more specific strain related information. Such information would 323 then be used to get estimates of the relative values of transmissibility β_i , viru-324 lence α_j , and even of shedding $(\bar{\zeta}_{jm})$ and environmental persistence $(\bar{\eta}_j)$. But 325 equally important in evaluating the impacts of vaccination strategies on local 326 outbreaks is obtaining strain-specific cross-immunity data (for characterization 327 of the elements $c_{i\ell}$ of the cross immunity matrix **C**), waning rates (which we 328 have not made strain specific, but our model could be generalized to include 329 strain specific values t_i^{half}), and the relative within host competition values (i.e., 330 λ_i , which we have set all equal to 1 at this time in the absence of data to the 331 contrary). Models are sorely needed to explore multistrain dynamics, partic-332 ularly the epidemiological properties with regard to shedding, environmental 333 persistence, transmission, mutation, and within-host replication rates, which 334 acting together determine the relative success of different strains and their ac-335 tual impact on the severity of epidemics and the nature of vaccination programs 336 needed to suppress them. 337

The process of making our model both location and strain specific could be 338 undertaken using methods designed to enhance the relevancy of models, such 339 as Appropriate Complexity Modeling (ACM: [26,37]). Further, in some cases it 340 may be useful to add spatial or age-structure information to our SEIVD model 341 IBMs or include a contact network [42], which itself may contain spatial or re-342 fined class category (e.g. age or work category) information. In addition, our 343 current implementation represents strain differences in terms of J loci with two 344 alleles (denoted by 0 and 1 respectively) at each locus. A more realistic repre-345 sentation of the genetic basis of strain differences may involve a more involved 346 genetic representation in which several alleles are possible at each locus. 347

Although cross-immunity and immune waning are entangled in our immu-348 nity modifier functions (i.e., ϕ_{ij} ; see Eq. A.11), cross-neutralization data can 349 be used to estimate the cross and waning immunity parameters using appro-350 priate methods [43,44]. Such data are becoming more widely available through 351 the application of rapid PCR methods [3, 45, 46]. Strain or variant cross neu-352 tralizing studies bring up a much neglected issue, which is the effect of dose 353 (number of pathogens involved in the initial infection, also know as viral load) 354 on the severity of the infection. This differs from the questions of the number 355 of doses—usually one or two—constituting and vaccine regimen versus the viral 356 load (or antigen load, or virus-like particle load when only antigens or parts of 357 viruses are administered) in each dose [4]. In the context of vaccination, both 358 these issues and the technology used to produce the vaccine [23] may well have 359 an impact on waning immunity half-lives and cross-immunity values. Thus, 360

Submitted to PNAS

the parameter values used in the model should ultimately be vaccine specific. Further, when it comes to determining waning and cross immunity parameter values, our model does not distinguish between individuals that have been infected with a particular strain or vaccinated with a valency related to that strain.

In the coming year, as we obtain more information on the nature of immunity 366 to SARS-CoV-2, it will become more apparent to us whether or not COVID-19 367 will settle into global endemicity [19,47]. If this is the case, then constant vigi-368 lance and a well designed vaccination program with respect to vaccinating the 369 370 young and implementing booster vaccinations with appropriate strain valency will become the order of the day. The J-RAMP presented here, with appropri-371 ate elaborations that will become evident through its future application, such as 372 being able to compute the best time to administer booster shots of the same or 373 different strain valencies to individuals, should play a decisive role in the ratio-374 nal design of effective and efficient COVID-19 vaccination programs worldwide. 375 This is made apparent from the simulations we present here that, depending on 376 the immunological characteristics of hosts and mutational rates of SARS-Cov-377 2, it may be harder than currently anticipated to extinguish COVID-19 in the 378 next few years through non-adaptive vaccination programs. Thus, we should 379 endeavor to adapt the strain valency of our vaccines as rapidly as possible to 380 the predominating SARS-Cov-2 strains, identified from ongoing monitoring and 381 surveillance programs. 382

Finally, the concept of runtime-alterable, modeling platforms (RAMPs), 383 with driver script and other coding platform integration, in our case devel-384 oped in Java with R platform integration and a JavaScript simulation driver 385 window, provides the first example of a new concept in model implementation 386 that facilitates model sharing and easy modification by users other than the 387 original developers. We believe such platforms can come to play an important 388 role not only in disease modeling, but in all fields of research that rely on models 389 for comprehensive analyses of the behavior of systems of interest. 390

³⁹¹ Materials and Methods

³⁹² Our SEIVD-IBM in a nutshell

We constructed an individual-based model (IBM) of a susceptible-exposed-393 infectious-recovered (i.e., an SEIVD model, where removed R are split into 394 V=immune/vaccinated, and D=dead) epidemiological process [11, 12] in a ho-395 mogeneous population with a random encounter contact rate parameter $\kappa_0 > 0$. 396 Our formulation includes a host immunological waning process [6, 19]. It also 397 includes the emergence of pathogen strains due to a mutational process that 398 impacts both transmission of mutant strains from the infectee and genetic 399 drift [3, 5, 48] of strains within the infector, with rates impacted by cross im-400 munity effects. We allowed for variation in pathogen strain transmissibility 401 (i.e., in the $\beta > 0$ parameter of the frequency dependent transmission function 402 $\beta SI/N$ [49, 50]) and pathogen virulence as represented by the disease-induced 403 host mortality rate sensu Anderson and May [51] (and often represented by a 404 parameter $\alpha \geq 0$ [49]). 405

Submitted to PNAS

422

423

429

430

431

432

433

434

435

436

43

438

439

440

441

442

443

444

445

446

447

448

449

450

The detailed formulation of our model and its algorithmic implementation is provided in Appendix A. In a nutshell we:

- 4081. defined a set of 2^J pathogen strains (user selected value for J ranging from4090 to 8; pathogen index $j = 0, ..., 2^J 1$) with a genetic-relatedness topology410of a J-dimensional unit cube—i.e., each pathogen has J-loci that can take411on one of two allelic values at each locus with immediate neighboring412strains differing from each other by exactly one allelic value (0 or 1) at413only one of the J loci
- 2. defined a population of N_0 hosts as belonging at time t to either an epidemiologically naïve set of susceptible individuals **S** of size $N_{\rm S}(t)$, a set **A** of $N_{\rm A}(t)$ identified agents A_i $(i = 1, ..., N_{\rm A}(t))$ whose epidemiological histories are known, or a set **D** of $N_{\rm D}(t)$ individuals that have died from the disease
- 3. allow pathogen strain-specific transmission "force" $(\bar{\beta}_j > 0)$ and virulence $(\alpha_j \ge 0)$ parameters to vary in value among one another within a defined range $\bar{\beta}_j \in [\beta_{\min}, \beta_{\max}]$ and $\alpha_j \in [\alpha_{\min}, \alpha_{\max}]$
 - 4. kept track of the total prevalence N_I as the sum of the prevalences of the individual strains N_{Ij}, j = 0, ..., 2^J − 1—i.e. N_I = ∑_{j=0}^{2^J-1} N_{Ij}
 5. introduced a random contact rate function κ(t) with a constant param-
- 5. introduced a random contact rate function $\kappa(t)$ with a constant parameter κ_0 that is Poisson distributed on [t, t+1), $t = 0, 1, \cdots$, multiplied by an adaptive response function that reduces the contact rate with increasing disease prevalence, such that the $\kappa(t)$ is reduced to $\kappa_0/2$ when the $N_{\rm I}(t)/(N_0 - N_{\rm D}) = p_{\rm I}^{\rm half}$ —see Eq. A.10 in Appendix A
 - 6. update the epidemiological state of the agents A_i with respect to each of the strains $j = 0, ..., 2^J 1$ where the state with respect to particular strain j at time t is represented by
 - (a) 0: has never been infected with this strain
 - (b) $E_j(t, \tau_{ij})$: infected at time $\tau_{ij} \leq t$ with this strain, but not yet infectious for an expected period of σ_E units of time
 - (c) $I_j(t, \tau_{ij})$: infectious at time t with this strain, for an expected period of σ_I units of time, having been most recently infected (reinfections with the same strain may occur) with this strain at time $\tau_{ij} < t$
 - (d) $V_j(t, \tau_{ij})$: has now recovered from its most recent infection at time τ_{ij} with this strain and has some level of waning immunity to it

where we assume that agent A_i can be infected at time t with at most one dominant strain (denoted by the index j), although it will have different levels of waning immunity to all of the strains to which it has been infected in the past

- 7. included waning immunity functions $\omega_{ij}(t)$ (symbol is omega: Eq. A.6) used to compute the level of immunity that agent A_i has to its most recent infection by strain j
- 8. included cross immunity constraints (a J^2 -matrix C) that apply both to the *infector* transmitting the pathogen and the *infectee* being invaded (inv) by the pathogen, both of which reduce the likelihood of infection and strain drift by strain j compared with closely related strains ℓ
- 9. computed an *infection probability* $\pi_{ih,j\ell}^{inf}$ that agent A_i infected with strain *j* infects agent A_h with strain ℓ in terms of a concatenation of infector viral shedding $(\zeta_{i\ell})$, viral persistence in the environment (ε_{ℓ}) , and viral transmission $(\beta_{h\ell})$ processes (Fig. 1)

Submitted to PNAS

455	10.	computed an <i>invasion probability</i> $\pi_{h\ell\ell'}^{inv}$ that an agent A_h infected with
456		strain ℓ becomes infectious with strain ℓ' as its major strain, in terms
457		of the multiplicative effects of viral mutation (μ) and viral replication
458		(λ_{ℓ}) processes ongoing within an infectee A _h during this infectees exposed
459		$(E_{\ell'\tau_{h\ell'}})$ and infectious $(I_{\ell'\tau_{h\ell'}})$ stages (Fig. 1)
460	11.	computed the overall probability $\pi_{ih,j\ell'}$ that that an infector A_i infected
461		with major strain j results in an infectee A_h expressing ℓ' as its major
462		strain
463	12.	implemented a discrete time individual-based stochastic SEIVD (here V
464		represents individuals that have either recovered from infection or have
465		been vaccinated, D represents cumulative dead) multi-strain model that
466		includes specifiable time-dependent univalent and multivalent vaccination
467		applications

468 Our J-RAMP implementation

Models of systems process can be coded as singular implementations model for-469 mulations using: i) highly efficiently compilable computer languages (e.g., C++, 470 FORTRAN, Java); or ii) less efficiently, but more easily coded, scriptable (e.g., 471 JavaScript, Python, Perl) computer languages. More conveniently and expedi-472 tiously, they can be coded up, as discussed in [52], using a systems modeling 473 platform, such as Matlab's SIMULINK, Mathematica, Stella, AnyLogic, Nu-474 merus, or Berkeley Madonna. Advantages of the latter include more rapid and 475 accurate model development, though simulations may be slowed down by plat-476 form overhead. Between these extremes, we propose a more general approach 477 to specific classes of systems' models, where the basic system structure is fixed, 478 but implementation of some elements can be easily and safely altered so that 479 optional implementations are presented at runtime. We call such a design run-480 time alterable-model platforms. (RAMPs); and here we present a Java RAMP 481 implementation of the SEIVD-IBM described in the previous subsection. 482

Submitted to PNAS

483

484

485

487

488

The characteristics we envision for a model platform to be a RAMP are:

1. RAMPs include a set of model parameters (constants) whose values can be selected or specified (sometimes within a predefined range of values) at simulation runtime using a switch, nob, slider, or text-entry window accessed via a platform graphical interface or dashboard (e.g., see Fig. 2 and Table 1 which apply to our SEIVD-IBM J-RAMP).

2. RAMPs include a specific set of *runtime alternative modules*, (RAMs),
where the original can be redefined in a graphical interface window, and
the unaltered original and the alternative routines are stored as a (preferably open-ended) numbered set. The original or any one of the alternatives
can be selected for use at runtime (for a list of functions in our RAMP
see Table 2).

RAMP implementations also provide an API for both remote and onboard scripting. This API enables control of all user aspects of the simulation, including the parameter set, run management, RAM options, and
data retrieval. Script logic can alter parameter settings and RAM options as the simulation progresses. A Nashorn-based Javascript interpreter enhanced with API methods is provided.

4. The API can be accessed remotely using operating system facilities by
external applications running concurrently with the simulator. Of particular interest is the ability to control the simulation from the R statistical
platform. An R routine can be formulated to both manage the simulation
run and to retrieve and process the resulting data. The RAMP simulation
becomes a "virtual package" to the controlling R logic. See Appendix B.

We implemented our RAMP using Java and made ample use of all of the fea-507 tures described above. Use of the RAM facility permitted experimentation with 508 the several versions of cross immunity presented in this paper. A Javascript pro-509 gram was used to control an adaptive vaccination strategy. A small R package 510 serving as a driver was used in an R program that ran the simulation multiple 511 times, extracted results into R data structures, and produced graphs showing 512 statistical mean and standard deviation. More details on the graphical structure 513 and implementation of our SEIVD-IBM are both implied in the presentation of 514 results below, and in additional details provided in Appendix B. 515

516 COVID-19 model assumptions and parameter values

The first variable that needs to be determined is the unit of time we use for 517 our simulations because all process rate parameters are scaled by its selection. 518 Since the time resolution of empirical COVID-19 incidence and mortality data 519 is daily, we selected are unit of time t to be days. Additionally, based on various 520 sources including a metapopulation study of COVID-19 parameter estimates 521 [53], we set the latent and infectious periods to be 4 and 7 days respectively. 522 Basic SEIR epidemiological models do not separate out the processes of contact 523 and transmission-per-contact, so we had some leeway on what values to choose 524 for contact rates and transmission rates per contact because it is the value of 525 the product of these that is important in determining the reproductive value, 526 commonly referred to as " R_0 " for COVID-19. Hussein et al.'s [53] meta analysis 527 of COVID-19 zeroed in on $R_0 = 3.14$ as a mean value across a range of studies 528

⁵²⁹ (95% confidence interval [2.69, 3.59]) though these authors suggested that the ⁵³⁰ most recent studies they looked at suggested that R_0 was more likely between ⁵³¹ 2 and 3.

Assuming no seasonal effects (i.e., $\delta = 0$ in Eq. 3), in our single strain runs we kept $R_0 \approx 3$ by setting $\kappa = 4$ (effective contacts per day, which nominally involves being with 6 feet of one another at least 15 mins) thereby requiring $\beta = 0.3$, because in the notation of the continuous time model introduced in Eq. A.29, we have an inverse latent period value of $\gamma \equiv 1/\sigma_{\rm E} = 1/4$ and an inverse infectious period value of $\rho \equiv 1/\sigma_{\rm I} = 1/7$ days (Table 1) for Eq. A.29 to yield $R_0 = \frac{4 \times 0.3}{1/4 + 1/7} = 3.05$

In our multistrain runs, we did allow for the emergence of strains that were more transmissible than this single strain value (in these runs new strains were in the range [0,0.475] (see table depicted in Fig. C.4). Also, although the incubation period is typically thought to have a median of 5 days, it can be much faster [54].

In reality, the contact rate κ is not constant, but is time varying. It is influ-544 enced by the social distancing behavior of individuals who may be responding 545 to fears of contracting the disease, or regulations imposed by local authorities 546 to reduce effective contact rates. To account for this, we formulated an adap-547 tive contact rate function $\kappa(t)$ (Eq. A.10) in terms of a function that declines 548 adaptively from a non-epidemic (baseline maximum) value κ_0 to $\kappa_0/2$ when the 549 prevalence (the percentage of the population infectious at time t) increases to 550 $\frac{N_{\rm I}(t)}{N(t)-N_{\rm D}(t)} = p_{\rm I}^{\rm half}$. In the illustrative simulations presented here, we explore the 551 effect of varying $p_{\rm I}^{\rm half}$ on the size of the shape of epidemic, but set $p_{\rm I}^{\rm half} = 0.002$ 552 (i.e., a prevalence level of 0.2%) as a baseline value, because in our simulations 553 this baseline value, along with the parameter values selected above, results in a 554 cumulative number of cases to just over 11% in a population of N = 100,000555 (Appendix C, Fig. C.3). This puts our illustrative baseline case in the ballpark 556 of the US outbreak which Worldometer reported to have a cumulative case level 557 of 8.5% ($\approx 284.5 \times 10^6/332.9 \times 10^6$) after one year, but this is likely to be a 558 substantial underestimate of the actual number of cases [55]. 559

To keep things simple in applying our model to a multistrain setting, we assumed that the immune effects on infector shedding and mutation and replication within the infectee through a cross-immunity processes, can be tweaked through a single constant $c \in [0, 1)$ (making the elements $c_{j\ell}$ of the matrix C strain-dependent will obviously require considerable supporting data). One scenario is to assume cross immunity only applies to nearest neighbors, i.e.:

Nearest-neighbor **C**:
$$c_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ c & \text{if } \ell \text{ differs from } j \text{ by one allele} \\ 0 & \text{otherwise} \end{cases}$$
 (1)

For other formulations, such as "Cascading **C**" or including escape mutations in the mix see Eqs. A.7 and A.9 in Appendix A.

Additionally, we expect this type of evidence to become increasing available with whole genome sequence of pathogen strains [56] collected during host shedding. For simplicity's sake, however, we assume that infectee with major strain j will shed minor strains in the immediate neighborhood of j at comparative

Submitted to PNAS

rate $\zeta \in [0, 1)$ and be major strain-independent: i.e., we assume

$$\zeta_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ \zeta & \text{if } \ell \text{ differs from } j \text{ by one allele} \\ 0 & \text{otherwise} \end{cases}$$
(2)

Third, again in the absence of evidence to the contrary, we assume that seasonal fluctuations are strain independent. In this case, for strain-independent constants $\delta \in [0, 1)$ and $\theta \in [-\pi, \pi]$ that set seasonal fluctuations related to environmental persistence, Eq. A.13 in the Appendix A simplifies for a single constant $\bar{\eta}$ to:

$$\eta_{\ell}(t) = \bar{\eta} \left(1 + \delta \sin \left(\frac{2\pi t}{365} + \theta \right) \right) \qquad \forall \ell \tag{3}$$

In our multistrain simulations, for purposes of illustration, we set both the shedding parameter ζ in Eq. 2 above and μ in Eq. A.16 to be 0.001. Obviously, it would be of considerable interest to know how the values of these two parameters impact strain proliferation, but this is left to future studies when data are available to guide simulations of realistic scenarios.

Acknowledgements and Funding Sources

⁵⁸⁴ This work was funded in part by NSF Grant 2032264 (PI: WMG).

585 References

- [1] Anderson RM. The impact of vaccination on the epidemiology of infectious
 diseases. In: The Vaccine Book. Elsevier; 2016. p. 3–31.
- [2] Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health
 and economic value of a hypothetical COVID-19 vaccine in the United
 States: Use of cost-effectiveness modeling to inform vaccination prioritiza tion. Vaccine. 2021;39(7):1157–1164.
- [3] Eguia RT, Crawford KH, Stevens-Ayers T, Kelnhofer-Millevolte L,
 Greninger AL, Englund JA, et al. A human coronavirus evolves antigeni cally to escape antibody immunity. PLoS pathogens. 2021;17(4):e1009453.
- Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 2020;20(10):615–632.
- [5] Koopman JS, Simon CP, Getz WM, Salter R. Modeling the population
 effects of epitope specific escape mutations in SARS-CoV-2 to guide vacci nation strategies. medRxiv. 2021;.
- [6] Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;.
- [7] Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, et al. Recombinant
 receptor-binding domains of multiple Middle East respiratory syndrome
 coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against
 divergent human and camel MERS-CoVs and antibody escape mutants.
 Journal of virology. 2017;91(1).
- [8] Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison
 EM, et al. SARS-CoV-2 variants, spike mutations and immune escape.
 Nature Reviews Microbiology. 2021;p. 1–16.
- [9] Saad-Roy CM, Levin SA, Metcalf CJE, Grenfell BT. Trajectory of in dividual immunity and vaccination required for SARS-CoV-2 community
 immunity: A conceptual investigation. Journal of the Royal Society Inter face. 2021;18(175):20200683.
- [10] Saad-Roy CM, Wagner CE, Baker RE, Morris SE, Farrar J, Graham AL,
 et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2
 over the next 5 years. Science. 2020;370(6518):811–818.
- [11] Willem L, Verelst F, Bilcke J, Hens N, Beutels P. Lessons from a decade of
 individual-based models for infectious disease transmission: a systematic
 review (2006-2015). BMC infectious diseases. 2017;17(1):612.
- [12] Chowell G, Sattenspiel L, Bansal S, Viboud C. Mathematical models to
 characterize early epidemic growth: A review. Physics of life reviews.
 2016;18:66–97.

- [13] Keskinocak P, Oruc BE, Baxter A, Asplund J, Serban N. The impact of
 social distancing on COVID19 spread: State of Georgia case study. Plos
 one. 2020:15(10):e0239798.
- ⁶²⁷ [14] Abueg M, Hinch R, Wu N, Liu L, Probert W, Wu A, et al. Modeling
 ⁶²⁸ the effect of exposure notification and non-pharmaceutical interventions
 ⁶²⁹ on COVID-19 transmission in Washington state. NPJ digital medicine.
 ⁶³⁰ 2021;4(1):1-10.
- [15] Chen PZ, Bobrovitz N, Premji Z, Koopmans M, Fisman DN, Gu FX. Het erogeneity in transmissibility and shedding SARS-CoV-2 via droplets and
 aerosols. eLife. 2021 apr;10:e65774. Available from: https://doi.org/
 10.7554/eLife.65774.
- [16] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble
 A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV2 as Compared with SARS-CoV-1. New England Journal of Medicine.
 2020;382(16):1564-1567. Available from: https://doi.org/10.1056/
 NEJMc2004973.
- [17] Maginnis MS. Virus-receptor interactions: the key to cellular invasion.
 Journal of molecular biology. 2018;430(17):2590-2611.
- ⁶⁴² [18] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K,
 ⁶⁴³ Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant
 ⁶⁴⁴ of concern 202012/1: matched cohort study. bmj. 2021;372.
- [19] Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern
 the transition of COVID-19 to endemicity. Science. 2021;371(6530):741–
 745.
- [20] Alizon S, Luciani F, Regoes RR. Epidemiological and clinical consequences
 of within-host evolution. Trends in microbiology. 2011;19(1):24–32.
- [21] Fenichel EP, Castillo-Chavez C, Ceddia MG, Chowell G, Parra PAG, Hick ling GJ, et al. Adaptive human behavior in epidemiological models. Pro ceedings of the National Academy of Sciences. 2011;108(15):6306–6311.
- Gozzi N, Bajardi P, Perra N. The importance of non-pharmaceutical in terventions during the COVID-19 vaccine rollout. medRxiv. 2021;Avail able from: https://www.medrxiv.org/content/early/2021/01/09/
 2021.01.09.21249480.
- [23] Kumar A, Dowling WE, Román RG, Chaudhari A, Gurry C, Le TT, et al.
 Status Report on COVID-19 Vaccines Development. Current Infectious
 Disease Reports. 2021;23(6):1–12.
- ⁶⁶⁰ [24] Chretien JP, George D, Shaman J, Chitale RA, McKenzie FE. In ⁶⁶¹ fluenza forecasting in human populations: a scoping review. PloS one.
 ⁶⁶² 2014;9(4):e94130.

- ⁶⁶³ [25] Getz WM, Gonzalez JP, Salter R, Bangura J, Carlson C, Coomber M,
- et al. Tactics and strategies for managing Ebola outbreaks and the salience
- of immunization. Computational and mathematical methods in medicine. 2015;2015.
- [26] Getz WM, Salter R, Mgbara W. Adequacy of SEIR models when epidemics
 have spatial structure: Ebola in Sierra Leone. Philosophical Transactions
 of the Royal Society B. 2019;374(1775):20180282.
- ⁶⁷⁰ [27] Drake JM. Limits to forecasting precision for outbreaks of directly trans-⁶⁷¹ mitted diseases. PLoS Med. 2005;3(1):e3.
- [28] Jefferies JM, Clarke SC, Webb JS, Kraaijeveld AR. Risk of red queen dynamics in pneumococcal vaccine strategy. Trends in microbiology. 2011;19(8):377–381.
- ⁶⁷⁵ [29] Thomas LJ, Huang P, Yin F, Luo XI, Almquist ZW, Hipp JR, et al. Spa⁶⁷⁶ tial heterogeneity can lead to substantial local variations in COVID-19
 ⁶⁷⁷ timing and severity. Proceedings of the National Academy of Sciences.
 ⁶⁷⁸ 2020;117(39):24180-24187.
- [30] Getz WM, Salter R, Luisa Vissat L, Horvitz N. A versatile web app for
 identifying the drivers of COVID-19 epidemics. Journal of Translational
 Medicine. 2021;19(1):1–20.
- [31] Da Silva RM, Mendes CF, Manchein C. Scrutinizing the heterogeneous
 spreading of COVID-19 outbreak in large territorial countries. Physical
 Biology. 2021;18(2):025002.
- [32] Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in
 contact patterns shape the dynamics of the COVID-19 outbreak in China.
 Science. 2020;.
- [33] Udwadia ZF, Raju RS. How to protect the protectors: 10 lessons to learn
 for doctors fighting the COVID-19 coronavirus. Medical Journal, Armed
 Forces India. 2020;.
- [34] Van Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19:
 Does the infectious inoculum dose-response relationship contribute to un derstanding heterogeneity in disease severity and transmission dynamics?
 Medical hypotheses. 2021;146:110431.
- [35] Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate
 mutation rate in the SARS coronavirus genome and its implications. BMC
 evolutionary biology. 2004;4(1):1–9.
- [36] Geoghegan JL, Holmes EC. The phylogenomics of evolving virus virulence.
 Nature Reviews Genetics. 2018;19(12):756-769.
- [37] Larsen LG, Eppinga MB, Passalacqua P, Getz WM, Rose KA, Liang
 M. Appropriate complexity landscape modeling. Earth-science reviews.
 2016;160:111-130.

- [38] Yang P, Yang G, Qi J, Sheng B, Yang Y, Zhang S, et al. The effect of mul tiple interventions to balance healthcare demand for controlling COVID-19
 outbreaks: a modelling study. Scientific reports. 2021;11(1):1–13.
- [39] Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT.
 The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proceedings of the National Academy of Sciences. 2020;117(48):30547–30553.
- [40] Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN,
 et al. Complete mapping of mutations to the SARS-CoV-2 spike receptorbinding domain that escape antibody recognition. Cell host & microbe.
 2021;29(1):44-57.
- [41] Brüssow H. COVID-19: emergence and mutational diversification of SARS CoV-2. Microbial Biotechnology. 2021;14(3):756-768.
- [42] Keeling MJ, Eames KT. Networks and epidemic models. Journal of the
 Royal Society Interface. 2005;2(4):295–307.
- [43] Roberts GO, Rosenthal JS, et al. General state space Markov chains and MCMC algorithms. Probability Surveys. 2004;1:20–71.
- [44] Lele SR, Dennis B, Lutscher F. Data cloning: easy maximum likelihood es timation for complex ecological models using Bayesian Markov chain Monte
 Carlo methods. Ecology letters. 2007;10(7):551–563.
- [45] Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL,
 Hudson WH, et al. Rapid generation of neutralizing antibody responses in
 COVID-19 patients. Cell Reports Medicine. 2020;1(3):100040.
- [46] Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. A high-throughput neutralizing antibody assay
 for COVID-19 diagnosis and vaccine evaluation. Nature communications.
 2020;11(1):1–6.
- [47] Tkachenko AV, Maslov S, Elbanna A, Wong GN, Weiner ZJ, Goldenfeld
 N. Time-dependent heterogeneity leads to transient suppression of the
 COVID-19 epidemic, not herd immunity. Proceedings of the National
 Academy of Sciences. 2021;118(17).
- [48] Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens. 2020;9(5):324.
- [49] Getz WM, Lloyd-Smith JO. Basic methods for modeling the invasion and
 spread of contagious diseases. DIMACS Series in Discrete Mathematics
 and Theoretical Computer Science. 2006;71:87.
- [50] McCallum H, Barlow N, Hone J. How should pathogen transmission be
 modelled? Trends in ecology & amp; evolution. 2001;16(6):295–300.

- [51] Anderson RM, May RM, et al. Coevolution of hosts and parasites. Para sitology. 1982;85(Pt 2):411-426.
- [52] Getz WM, Salter R, Lyons AJ, Sippl-Swezey N. Panmictic and clonal
 evolution on a single patchy resource produces polymorphic foraging guilds.
 PloS one. 2015;10(8):e0133732.
- [53] Hussein M, Toraih E, Elshazli R, Fawzy M, Houghton A, Tatum D, et al.
 Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2.
 Annals of surgery. 2021;273(3):416–423.
- ⁷⁵⁰ [54] Grimm V, Mengel F, Schmidt M. Extensions of the SEIR model for the analysis of tailored social distancing and tracing approaches to cope with COVID-19. Scientific Reports. 2021;11(1):1–16.
- [55] Wu SL, Mertens AN, Crider YS, Nguyen A, Pokpongkiat NN, Djajadi S,
 et al. Substantial underestimation of SARS-CoV-2 infection in the United
 States. Nature communications. 2020;11(1):1–10.
- ⁷⁵⁶ [56] Munnink BBO, Nieuwenhuijse DF, Stein M, O'Toole Å, Haverkate M,
 ⁷⁵⁷ Mollers M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analy ⁷⁵⁸ sis for informed public health decision-making in the Netherlands. Nature
 ⁷⁵⁹ medicine. 2020;26(9):1405–1410.
- [57] Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens per sist on inanimate surfaces? A systematic review. BMC infectious diseases.
 2006;6(1):1–8.
- [58] Liu X, Huang J, Li C, Zhao Y, Wang D, Huang Z, et al. The role of
 seasonality in the spread of COVID-19 pandemic. Environmental research.
 2021;195:110874.
- ⁷⁶⁶ [59] Valtonen A, Molleman F, Chapman CA, Carey JR, Ayres MP, Roininen
 ⁷⁶⁷ H. Tropical phenology: Bi-annual rhythms and interannual variation in an
 ⁷⁶⁸ Afrotropical butterfly assemblage. Ecosphere. 2013;4(3):1–28.
- [60] Getz WM, Salter R, Muellerklein O, Yoon HS, Tallam K. Modeling epi demics: A primer and Numerus Model Builder implementation. Epidemics.
 2018;25:9–19.
- Interpretation [61] Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G, Trabes A, et al. SARS-CoV-2 within-host diversity and transmission.
 Science. 2021;372(6539). Available from: https://science.sciencemag.
 org/content/372/6539/eabg0821.
- [62] Jones JH. Notes on R0. Califonia: Department of Anthropological Sciences.
 2007;323.

Getz et al., June 7, 2021

⁷⁷⁸ Figures and Tables




Figure 1: An overview of the processes included in our SEIVD-IBM model. The probability $\pi_{ih,jl}^{\inf}$ of A_h being infected primarily with pathogen ℓ in terms of receiving an effective dose from agent A_i , (η) is computed in terms of a concatenation of shedding rates $(\zeta_{i\ell})$, environmental persistence rates (ε_{ℓ}) , and host transmission $(\beta_{h\ell})$ processes (Eq. A.15) and includes both waning and cross immunity factors. The probability $\pi_{h\ell\ell'}^{inv}$ that the dominant strain emerging in host A_h is strain ℓ' given initial infection with strain ℓ is computed in terms of within-host mutation and within-host replication process (Eq. A.16) and also includes both waning and cross immunity factors. These two probabilities are then used to compute the overall probability $\pi_{ih,j\ell'}$ (Eq. A.17) that infector *i*, infected with major strain *j*, infects infectee *h* with major strain ℓ' . The quantity $R_{\text{eff}}(t')$ is the expected number of individuals each infectious agent is expected to infect around time $t' \in [t + \sigma_{\text{E}}, t + \sigma_{\text{E}} + \sigma_{\text{I}}]$, where $R_0 = R_{\text{eff}}(0)$ is estimated for our model using Eq. A.29. Equation references for the other mathematical functions provided in this figure are given in Table 2.

Getz et al., June 7, 2021




Figure 2: A. The dashboard of our Java Runtime-Alterable-Model Platform (J-RAMP) SEIVD (S=susceptibles, E=exposed, I=infectious, V=immune, D=dead) individual-based model (IBM) and simulations obtained using the parameters values depicted in the slider windows (also see Table 1). The top left window of this dashboard contains information on the final state of the population (in this case S = 2135and D = 165 in a population of $N_0 = 10,000$, the bottom left bar graph of dashboard panel is the final values of E, I, V and D at epidemic cessation at time t = 166 (days) or the simulation run time, whichever comes first. Dashboard also shows a graph of incidence and cumulative deaths (purple and black: selected using colored buttons below the graph). The bottom ribbon of the dash board has a series of radio buttons that respectively open a Log, a JavaScript (JS), and a Scripting (S) window, Line and Bar graph windows (for multistrain runs), as well as windows for controlling vaccination strategies (V), listing realtime agent information (A), pathogen parameter values (P), monitoring probability computations (Intern), coding and controlling runtime alternative operations (Op), and three runtime buttons (Reset, Step, Run). B. Graphs of prevalence (cut out from main panel when only the red button is on) and C. daily deaths (crimson button) are pasted below the dashboard.






Figure 3: Plots of prevalence (I: red) and dead (D: black) individuals for simulations using the parameter values given in Table 1 with N = 10,000. The waning immunity half-life values are $t^{\text{half}} = 90,120$ or 180, as labeled. In the top two panels the contact rate is constant, while in the bottom two panels it is adaptive with $p_{\text{I}}^{\text{half}} = 0.05$ or 0.01 as labeled (Eq. A.10). Note that the adaptive case approaches the constant case as $p_{\text{I}}^{\text{half}} \to \infty$ and that the vertical axis in the four panels each have different scale, though the horizontal time axes is the same in all four case (365 days).




Figure 4: Incidence (ΔI^+ : purple) is plotted over 3 years for the baseline run (parameters given in Table 1 with $N = 100,000, p_I^{half} = 0.002$, and $t_v^{half} = 365$) for the cases where vaccination rates v(t) (indicated by blue lines) are applied during the second and third years only to individuals not previously vaccinated selected at random (**A**. v(t) = 0.001, **B**. v(t) = 0.002) and to individuals not previously vaccinated and who also have not previously been infected with SARS-CoV-2 (**C**. v(t) = 0.002).

Getz et al., June 7, 2021




Figure 5: The total daily incidence (ΔI +: purple) and strain-specific prevalence (I: red) individuals for a 16-strain epidemic burning through a population of size N = 100,000 are plotted over a 3-year period for the cases where cross-immunity is absent (A. c = 0.0) or intermediate among nearest neighbors differing by one allele (B. c = 0.5). The remaining parameters are listed in Table 1 and for all strains include the same host transmission ($\bar{\beta} = 0.3$) and virulence ($p_{\alpha} = 0.02$), waning half-life $t^{\text{half}} =$ 365, minor strain shedding $\zeta = 0.001$ and within host mutation ($\mu = 0.001$) parameter values. Note that each panel has its own vertical scale and that the horizontal scales are set by the J-RAMP and are 0-1100 days for the incidence curves and 0-1250 days for the prevalence curves, although all curves are drawn to 1100 days. Dominant or codominant strains are labeled in red (number and equivalane allele representation), while minor strains are labeled in light grey.




Figure 6: Daily incidence (deep purple curves) and prevalence of individual strains (red curves; with strain number labels plotted in order of emergence over time) that exceed a maximum prevalence of 12 individuals at any time are plotted over a three year period ($t \in [0, 1100]$ days), firstly, for three cases (A.-C. in a system with nearestneighbor only cross-immunity (labeled "simple", see Eq. 1) and, secondly, in two cases (D. and F.) in a system with cascading cross-immunity (Eq. A.7). In the first three cases we have: A., no vaccination (blue labels); an B. & C., a vaccination rate of v = 0.002 applied in years 2 and 3 ($t \in [365, 110]$) to individuals who have not previously been vaccinated, respectively for the cases of univalent vaccines (strain 0, green labels and strain 127, brown labels). In the fourth case, \mathbf{D} , a quadravalent vaccine (strain 0, 7, 31 & 127; plum labels) is applied at a vaccination rate of v =0.01 (i.e., 1%) at random, irrespective whether or not individuals selected have been previously vaccinated (or ill with COVID-19). In the fifth case, \mathbf{E} ("robust immunity") case"), a bivalent vaccine (strains 0 & 127; orange labels) is applied, as in cases **B**. & C., at a vaccination rate of v = 0.002 (i.e., 1%) at random to individuals selected that have been previously vaccinated. In this latter case, however immune waning has been reduced by a factor of 5 ($t^{\text{half}} = 1825$ days) with cascading cross immunity increased from c = 0.5 to c = 0.9. The dashboards for all these cases, and miniature prevalence plots of all 128 strains for each of these four cases can be found in Figs. C.5-C.9 in the Appendix. The parameter values are the same as in Fig. 5B, apart from the immune parameters being greatly strengthen in the "robust immunity case" E., and in all cases strain specific transmission parameter values β_j (j = 0, ..., 127) that were randomly assigned values between 0 and 0.3, except for the increasingly dominant strain sequence $\beta_0 = 0.3 \ (0 \equiv (0, 0, 0, 0, 0, 0, 0)), \ \beta_1 = 0.325 \ (1 \equiv (0, 0, 0, 0, 0, 0, 1)),$ $\beta_3 = 0.35 \ (\equiv (0, 0, 0, 0, 0, 1, 1)), \dots, \beta_{127} = 0.475 \ (127 \equiv (1, 1, 1, 1, 1, 1, 1)) \ (\text{particular})$ values of β_i are provided for the different strains depicted here; see Table in Fig. C.4 for all values of β_j , j = 0, ..., 127). Note that the vertical axis are all on the same scale height for incidence, but are individually scaled for prevalence, while the time axis are all on the same scale for the prevalence curves which differs from the incidence curves, which among themselves are all on the same time scale.

Getz et al., June 7, 2021




Figure 7: The daily incidences (vertical axis: number of individuals) are plotted over time (horizontal axis: number of days; plots have been squashed to ensure they are all on the same time scale) for two cases: **A.** adaptive vaccination for nearest-neighbor only cross immunity (Eq. 1) and **B.** adaptive vaccination for cascading cross immunity case (Eq. A.7), and should be compared with the non-vaccination case depicted in Fig. 6A and the non-adaptive vaccination case depicted in Fig. 6D. As in this latter non-adaptive case, vaccination is performed on non-infectious individuals, selected at random (i.e., re-vaccinations can occur) at a rate of 1% per day, but now the dominant strain is targeted, as well as a second strain if its prevalence exceeds 10 cases, with vaccine valency switches every 90 days. The realized adaptive vaccine valencies for these two runs are indicated by colored bars on the horizontal time axis (red, valency is (0,127); brown, valency is (127); orange, valency is (23); green, valency is (102)).

Parameter	Symbol	Value	Source/Comment				
Single strain simulations							
Time unit	t	daily	Goldilocks value [*]				
Nominal pop size	N_0	1 to 10 $\times 10^4$	Goldilocks value [‡]				
Basic contact rate	κ_0	4 per day	effective contacts †				
Transmission	β	0.3	ensures $R_0 \approx 3^+$				
Latent Period	$\sigma_{ m E}$	4 days	median time in \mathbf{E}^{\P}				
Infectious period	$\sigma_{ m I}$	$7 \mathrm{days}$	median time in I^{\S}				
Immunity half-life	t^{half}	1/4 to 1 year	per run specs.				
Disease-induced mort.**	p_{lpha}	2% of cases	mortality rate is $\alpha^{\#}$				
Adaptive contact param. ^{*†}	$p_{ m I}^{ m half}$	0, 0.002, 0.05	reduces κ from κ_0				
Seasonal fluctuation param.	δ	0	seasons ignored $^{*+}$				
Multi strain simulations (single strain parameter values for all strains if not mentioned below)							
Mutation rate ^{$*\ddagger$}	μ	$0.001^{*\#}$	See Eq. A.16				
Strain number	$j = 0,, 2^J - 1$	J is 1 to 8	i.e., 2 to 1024 strains				
Cross immunity	c_{jm}	0 & 0.5	See Eq. 1				
Pathogen shedding	$ar{\zeta}_{jm}$	$0.001^{*\#}$	See Eq. A.12				
Environmental persistence	$ar\eta_j$	1 for all j	See Eq. A.13				
Transmission	$ar{eta}_j$	[0, 0.475]	per run specs.				
Within-host replication rate	λ_j	1 for all j	See Eq. A.16				
Disease-induced mort.**	p_{lpha_j}	[0, 0.05]	per run specs.				

Table 1: Parameter values used to simulate single and multistrain outbreaks

*Weekly unit produced excessive variation (see SOI)

[‡]Trade-off between excessive demographic stochasticity and simulation run time

 $^{\dagger}\textsc{Sufficiently}$ long and close to make transmission possible (also see Eq. A.29)

+See Eq. A.29

[¶]Reciprocal of γ in continuous time computation of R_0 per Eq. A.29

 $^{\S}\textsc{Reciprocal}$ of ρ in continuous time computation of R_0 per Eq. A.29

See Eq. A.6: note w(t) switches from 1 to 0 as immunity goes from complete to absent

 $\#{\rm This}$ is "virulence" parameter of continuous-time SEIR models

**If $\alpha << 1$ then $p_{\alpha_j} = 1 - e^{-\alpha} \approx \alpha$

^{*†}See Eq. A.10. Mostly 0.002 is used. Setting $p_{\rm I}^{\rm half} = 0$ implements $\kappa(t) = \kappa_0$, though $\kappa(t) \to \kappa_0$ as $p_{\rm I}^{\rm half} \to \infty$

*+Implies values of k and θ in Eq. A.13 are irrelevant

 $^{*\ddagger} \mathrm{Strain}$ independent—strain dependence requires more elaborate model

 $^{\ast\#}\textsc{Quantifies}$ the pass-on rate of mutations rather than the mutational rate of a locus or gene

***If $\alpha_j \ll 1$ then $p_{\alpha_j} = 1 - e^{-\alpha_j} \approx \alpha_j$

Table 2: Variables, indices and functions used in the model

Symbols	Variables and indices	Equation		
Variables				
$N_{\rm S}(t), N_{\rm A}(t), N_{\rm D}(t)$	size of sets \mathbf{S} , \mathbf{A} and \mathbf{D}	Eq. A.1		
J,j,m,ℓ and ℓ'	strain entropy and indices $(0,, 2^J - 1)$	Eq. A.2		
$N_{\mathrm{I}}(t), N_{\mathrm{I}_{j}}(t)$	$N_{\rm I}(t), N_{{\rm I}_j}(t)$ number of infectious: total and strain j at time			
A_i, A_h	specific agents $i, h = 1,, N_A(t)$ in set A	Eq. A.4		
Functions				
$\omega_{ij}(t)$	waning immunity of A_i w.r.t. strain j	Eq. A.6		
$\kappa(t)$	adaptive contact rate	Eq. A.10		
$\phi_{ij}(t)$	immunity modifier	Eq. A.11		
$\zeta_{ij}(t)$	shedding rate of strain j by infector A_i	Eq. A.12		
$\eta_\ell(t)$	environmental persistence	Eq. A.13		
$\beta_{h\ell}(t)$	strain transmission to infect ee \mathbf{A}_h	Eq. A.14		
$\pi_{ih,j\ell}^{\inf}(t)$	probability A_i infects A_h	Eq. A.15		
$\pi_{h\ell\ell'}^{\mathrm{inv}}(t)$	probability ℓ' is major strain when ℓ invades	Eq. A.16		
$\pi_{ih,j\ell'}(t)$	probability ℓ' is major strain in A_h when j is major strain in A_i	Eq. A.17		

¹ APPENDICES

² A Model Construction

³ Here we formulate an individual-based or agent-based (ABM) SEIR epidemio-

4 logical model to include host immunological waning and pathogen genetic drift

⁵ with variation across strain transmissibility and virulence. [1]

⁶ Assumptions, definitions, and states

The population consists of a well-mixed pool of N_0 individuals that is homogeneous except for the fact that some are uninfected (denoted S), some currently infected (E: exposed and not yet infectious; I infectious and asymptomatic or symptomatic) or have been infected and are now either dead (D) or recov-10 ered/vaccinated with some level of immunity (V) to one or more of 2^{J} pathogen 11 strains. This immunity wanes over time and its current level, augmented by 12 specified levels of strain cross-immunity, factored into an agent specific time-13 dependent strain-resistance function that impacts the shedding of mutant strains 14 by infectors and the within-host replication rates of mutant strains in infectees. 15 At the start of the epidemic, all individuals are assumed to encounter, on 16 average, $\kappa_0 > 0$ other individuals during each time period [t, t+1], but this 17 "effective contacts" rate adaptively decreases with increasing prevalence of the 18 disease due to the implementation of non-pharmaceutical interventions (social 19 distancing, hand washing, mask wearing, and other hygienic precautions). In 20 our selection of epidemiological parameter values, a unit of time is taken to be a 21 24-hour day. Other scalings of time would then require appropriately adjusted 22 epidemiological parameter values. Refined versions of the model could include 23 age-related parameter values and contact rates, as well as contact tracing, quar-24 antining, and isolation of infected individuals; but these will not be considered 25 here. 26

Initially, at model time t = 0, all individuals are considered SARS-CoV-27 2 naïve susceptible apart from one individual who is considered to have just 28 entered the infectious stage, infected by a pathogen designated as pathogen 29 strain 0 (wildtype). Throughout the model simulation, the N_0 agents in the 30 population are partitioned into three disjoint sets: the set of SARS-CoV-2 naïve 31 individuals, $\mathbf{S}(t)$, containing $N_{\mathbf{S}}(t)$ (the susceptibles); the set of identified agents, 32 $\mathbf{A}(t)$, containing $N_{\mathbf{A}}(t)$ individuals who are either currently infected (time t) 33 with a particular strain of SARS-CoV-2, or have some level of waning immunity 34 to one or more strains of SARS-CoV-2; and the set of dead individuals $\mathbf{D}(t)$, 35 currently of size $N_{\rm D}(t)$. Only the individuals in $\mathbf{A}(t)$ are uniquely identified as 36 they become infected for the first time and make the transition from set $\mathbf{S}(t)$ to 37 set $\mathbf{A}(t)$, where they are sequentially labeled using the index $i = 1, ..., N_{\mathbf{A}}(t)$. 38 The single infected individual at time zero will be designated Agent 1 (also 39 known as patient zero and denoted by A_1). Thus at time t it follows that 40

$$N_{\rm S}(t) + N_{\rm A}(t) + N_{\rm D}(t) = N_0 \quad (\text{a constant}) \tag{A.1}$$

We note that individuals in set $\mathbf{A}(t)$ can be in a disease state E or I with respect to pathogen j, but simultaneously can be in multiple immune states if Submitted to PNAS

⁴³ they have been infected with more than one pathogen strain in the past. We also

⁴⁴ note that the distinction between symptomatic and asymptomatic individuals ⁴⁵ in state I will not be considered here: and only need be incorporated if testing,

⁴⁵ In state I will not be considered here; and only need be incorporated if testi ⁴⁶ quarantining, and treatment processes are included in the model.

The total number of pathogen strains is set by a parameter J > 0, where each pathogen is represented by a *J*-bit binary number. Thus, there are 2^J possible strains indexed by $j = 0, 1, 2, ..., 2^J - 1$ where *j* is the decimal equivalent that corresponds to a given binary string. The initial strain, j = 0 is the binary string of *J* zeros.

Sets of stochastic epidemic events (i.e., transitions from classes S to E, E to I, I to V or D) are implemented at consecutive integer points in time (one set of events for each point in time). Events will only be considered on individuals that have been infected by at least one of the pathogens at some time after t = 0(this means that initially the epidemic computation proceeds rather rapidly, but becomes more computationally intensive for each time step as time proceeds).

58 Pathogen set

At the start of the simulation (t = 0), the set of potential pathogens indexed 59 by $j = 0, ..., 2^{J} - 1$ is generated along with its associated environmental persis-60 tence $(\bar{\eta}_j)$, transmission $(\bar{\beta}_j)$, within host replication (λ_j) and disease-induced 61 mortality rate (probability of dying from the disease p_{α_j}) parameters. These 62 may be specified or drawn from underlying distributions (e.g., the uniform dis-63 tributions $\beta \sim \text{Uniform}[\beta_{\min}, \beta_{\max}]$ and so on). Also, our model includes two 64 $2^J \times 2^J$ matrices of constants that are associated with pathogen mutations dur-65 ing strain shedding (elements ζ_{im}) and cross-immunity (elements c_{im}) processes 66 and thus involve but are conditioned on either the major strain that an infector 67 is harboring or on immunological state of the agents involved. These are the 68 shedding and cross-immunity matrices with elements $j, m = 1, ..., 2^{J} - 1$, Thus 69 we generate the following list of parameters associated with our 2^{J} pathogen 70 strains: 71

Pathogen list = (A.2)

$$\{(\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j}; \zeta_{jm} \text{ and } c_{jm} \text{ for } m = 0, ..., 2^J - 1) \mid j = 0, ..., 2^J - 1\}$$

72 Agent states

⁷³ In accordance with the above set of assumptions, each agent has the following ⁷⁴ basic disease states at time t, where disease states in agent A_i are referenced by ⁷⁵ the time $\tau_j > 0$ at which the most recent infection with strain j has occurred ⁷⁶ (an individual may be re-infected after immunity to the strain has waned to ⁷⁷ relatively low levels):

⁷⁸ 1. S(t): An individual who at time t has not been infected with any strain ⁷⁹ of the pathogen up to time t. All these individuals belong to set S(t)

2. $E_j(t, \tau_{ij})$: An agent A_i who was infected with strain j at time τ_{ij} , but has not yet become infectious (this is an individual in the latent stage that lasts for σ_E units of time). All these individuals belong to set $\mathbf{A}(t)$ Submitted to PNAS

94

- 3. $I_j(t, \tau_{ij})$: An agent A_i who is currently infectious with strain j, after being 83 infected with strain j at time τ_{ij} (this is the infectious stage that lasts for 84 $\sigma_{\mathbf{I}}$ units of time). All these individuals belong to set $\mathbf{I}(t) \subseteq \mathbf{A}(t)$ 85
- 4. $V_j(t, \tau_{ij})$: An agent A_i who was infectious with strain j, having been 86 infected with strain j at time τ_{ij} , but is now non-infectious with regard to 87 this strain—that is, recovered with some immunity to strain j, as well as 88 some cross immunity to strains closely related to j. All these individuals 89 belong to set $\mathbf{A}(t)$ 90

5. D(t): An individual at time t who has died after being exposed to and 91 become infectious with some strain of the pathogen. In a refined version 92 of the model, a record will be kept of the time of death and the strain that 93 caused death. All these individuals belong to set $\mathbf{D}(t)$.

Since an agent A_i may be infected over time by more than one strain j, its 95 complete epidemiological state is represented by a list 96

$$A_i(t) = \{ \text{state w.r.t. pathogen } 0, \dots, \text{state w.r.t. pathogen } 2^J - 1 \}$$
 (A.3)

If a living agent does not fall into any of the categories 2-4 with respect to pathogen j, we denote its epidemiological state at position j as \emptyset (the empty set). Consequently, if an agent A is susceptible at time t (i.e., an element of S(t), then we write

$$A_0(t) = \{\emptyset, \dots, \emptyset\} \in \mathbf{S}$$

However, while such individuals are omitted from the A list (hence we did not 97 subscript the agent A above), they may be recognized as "virtual members" 98 with this implicit state. Some other examples are: 99

• If $A_i(t)$ is infected, but not vet infectious, with pathogen strain j at time t but has not been infected with any other pathogen in its past history, then

$$A_i(t) = \{\emptyset, \cdots, \emptyset, E_j(t, \tau_j), \emptyset, \cdots, \emptyset\}$$

• On the other hand if A_i recovered from an infection with pathogen 0 at time τ_0 , and is now in infectious with pathogen j at time t, having become infected with this pathogen at time τ_i then we write

$$A_i(t) = \{ V_0(t, \tau_0), \emptyset, \cdots, \emptyset, I_j(t, \tau_j), \emptyset, \cdots, \emptyset \}$$

As we shall see, an agent history may contain at most one instance of either E_i 100

or I_i , while possibly containing multiple instances of V_i . 101

Agent and index sets 102

At the start of each time period, we update the set of identified agents A by 103 adding susceptibles that became infected with pathogens during the previous 104 time period and removing agents that died during the previous time period. 105 Thus if \mathbb{I}_A is the index set for non-empty elements of \mathbf{A} , with new indices added 106

Submitted to PNAS

for newly infected susceptibles and indices removed for individuals that died,then by definition:

$$\mathbf{A}(t+1) = \{ \mathbf{A}_i(t+1) | i \in \mathbb{I}_{\mathbf{A}}(t+1) \}$$
(A.4)

where the number of indices in the updated set $\mathbb{I}_{A}(t+1)$ is $N_{A}(t+1)$ and the updated number of dead is $N_{D}(t+1)$ at time t+1.

For mathematical convenience all susceptibles S will also be referred to as A₀:, i.e., there are $N_{\rm S}(t)$ individuals referenced by A₀ at time t. It will be useful to partition the set $\mathbf{A}(t)$ itself into three subsets at time t by identifying the sets $\mathbf{E}(t)$ and $\mathbf{I}(t)$ which respectively contain all agents that are currently in a state $\mathbf{E}_j(t)$ or a state $\mathbf{I}_j(t)$ at time t for some $j = 0, ..., 2^J - 1$. We note the intersection of these two sets is empty—i.e., $\mathbf{E}(t) \cap \mathbf{I}(t) = \emptyset$ —as will become apparent below from the transmission process rules set up below. We will use the notation

$$\mathbf{A}_{\mathrm{S}}(t) = \mathbf{A}(t) \setminus \left(\mathbf{E}(t) \cup \mathbf{I}(t) \right) \tag{A.5}$$

to denote the set of agents in $\mathbf{A}(t)$ but not in $\mathbf{E}(t)$ or $\mathbf{I}(t)$.

We also identify the set of infectious agents with infectious strain j. If A^j denotes an agent whose epidemiological state contains an entry $I_i(t, .)$, then

$$\mathbf{I}_{j}(t) = \{\mathbf{A}_{i_{1}}^{j}(t), \mathbf{A}_{i_{2}}^{j}(t), \dots, \mathbf{A}_{i_{N_{\mathbf{I}_{j}}}}^{j}(t)\},\$$

where the number of such agents is denoted by $N_{I_i}(t)$, and its index set by

$$\mathbb{I}_{\mathbf{I}_{i}}(t) = \{i_{1_{i}}, \dots, i_{N_{\mathbf{I}_{i}}}(t)\}.$$

¹¹⁹ Epidemiological processes

120 Immunity

In compartmental SIRS and SEIRS models, a concept of waning immunity and 121 its impact on epidemics is associated with the rates at which individuals in class 122 R revert back to class S. In agent-based SIRS and SEIRS models, we have the 123 opportunity to consider the immunological history of individuals and, hence, 124 can take a more refined approach to the complex process of how pathogens in 125 an infector A_i are passed on the an infectee A_h . Here we model this as a prob-126 ability generated from a concatenation of rates that include pathogen shedding 127 by A_i , the survival of pathogens in the environment, whether contained in feces, 128 urine, sweat, mucosal secretions or water droplets excreted by an infector, and 129 a process whereby pathogens gain access to a host (entering through wounds, 130 mucosal membranes or other membranes in the pulmonary or alignmentary sys-131 tems). We then characterize pathogen within-host strain replication rates in 132 terms of pathogen mutational and reproductive processes. The final outcome 133 in our model is either host recovery with some immunity or host death. We 134 also consider the induction of host immunity through vaccination and make the 135 assumption that waning immunity is the same, whether it stems from natural 136 infection or vaccination. Of course, these may be modelled in different ways 137 should data become available to make this distinction an important modeling 138

Submitted to PNAS

139 consideration.

140

Waning immunity. Recall that we use A_0 to denote an anonymous (generic) member of **S** and that A_i for i > 0 refers to a specific individual with an associated state list/vector. If some specific A_i is in immune state V_j having been infected with this strain at time τ_{ij} , we assume that the level of relative susceptibility of agent A_i to reinfection by strain j is given by (noting that the existence of the value τ_{ij} implies that infection of individual i by strain j at time τ_{ij} ensures that the V_j is no longer "null")

$$\omega_{ij}(t,\tau_{ij}) = \begin{cases} 0 & \text{if } \mathbf{V}_j \text{ is null} \\ \frac{1}{1 + \left((t - \tau_{ij} - \sigma_{\mathbf{I}} - \sigma_{\mathbf{E}})/t_j^{\text{half}}\right)^{\sigma}} & \text{if } t \ge \tau_{ij} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \\ 1 & \text{if } t < \tau_{ij} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \end{cases}$$
(A.6)

We note the following: 1.) the first case implies that τ_{ij} has yet to be defined; 2.) 148 the second case is equivalent to the statement that $\tau_{ij} \geq 0$ now exists for strain 149 j, since this occurs at time $t = \tau_{ij}$ (through the invocation of state $E_j(t, \tau_{ij})$); 150 3.) $\omega_{ij}(t,\tau)$ ranges from 1 (i.e. full "on") at $t = \tau + \sigma_{\rm I} + \sigma_{\rm E}$ and decays to 151 0 as $t > \tau + \sigma_{\rm I} + \sigma_{\rm E} \rightarrow \infty$; 4.) agent *i* cannot be reinfected with its current 152 major strain or with any other strain while it is currently itself in any state E_i 153 or I_j for any $j = 0, ..., 2^J - 1; 5.$ the larger the value of σ the steeper or more 154 abrupt the switch is from full immunity (equal to 1) at time τ through 1/2 at 155 time t_i^{half} to approach 0 as $t \to \infty$ (we set $\sigma = 4$ as providing an intermediate level of abruptness). 157

158

¹⁵⁹ Cross immunity with escape mutations. A somewhat more general implemen-¹⁶⁰ tation of cross-immunity may be based on the number of alleles by which strains ¹⁶¹ j and ℓ differ. If they differ in k positions, then the level of cross immunity can ¹⁶² be set to c^k . In this case

Cascading C:
$$c_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ c^k & \text{if } \ell \text{ differs from } j \text{ by } k \text{ alleles and } \ell \end{cases}$$
 (A.7)

In addition to this, one may also designate certain changes in certain alleles as
"escape mutants" with respect to the progenitor strain. For these, the level of
cross-immunity would be set to zero. Under these assumptions, a generalization
of Eq. A.7 would be

Escape mutation:
$$c_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ c^k & \text{if } \ell \text{ differs from } j \text{ by } k \text{ alleles} \\ & \text{and } \ell \text{ is not an escape mutation} \end{cases}$$
 (A.8)
0 & if $\ell \text{ is an escape mutation}$

In particular, for the case J = 7, if strain (1, x, x, x, x, x, x) is an escape mutation with respect to some level of immunity to strains (0, x, x, x, x, x, x), then Eq. A.8 becomes

$$c_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ 0 & \text{if } j \le 63 \text{ and } \ell > 63 \\ c^k & \text{otherwise, where } \ell \text{ differs from } j \text{ by } k \text{ alleles} \end{cases}$$
(A.9)

33

Submitted to PNAS

¹⁷⁰ Vaccination. A vaccine may be designed to give immunity to one or more ¹⁷¹ particular identified strain j. Vaccination strategies include vaccinating at a ¹⁷² fixed rate v(t) (percent of individuals vaccinated at each time period) over a ¹⁷³ fixed period that begins at t_v^{on} and ends at t_v^{off} and can focus on drawing only ¹⁷⁴ on: i) individuals in the set \mathbf{S} , ii) any non-infectious individual in \mathbf{S} or \mathbf{A} , or iii) ¹⁷⁵ any non-infectious, not previously vaccinated individual in \mathbf{S} or \mathbf{A} . The vaccine ¹⁷⁶ itself can be designed as follows:

- Dominant strain vaccination at time τ_{vac} . An individual S or A_i vaccinated with the dominant strain, say j, at time $\tau_{\text{vac}} \in [t_v^{\text{on}}, t_v^{\text{off}}]$ serves to add the disease state $V_j(t, \tau_{\text{vac}})$ to that individual's list. If the individual is already in state $V_j(t, \tau')$ at time $t > \tau_{\text{vac}}$, then its status is updated so that at time $t > \tau_{\text{vac}}$ it is now $V_j(t, \tau_{\text{vac}})$ rather than $V_j(t, \tau')$
- Multi-strain vaccination at time t_{vac} . An individual S or A vaccinated with a multi strain concoction at time $\tau \in [t_v^{\text{on}}, t_v^{\text{off}}]$, say with strain j_1, \ldots, j_{ν} , will have their disease status updated with regard to all these strains, as in the dominant strain case.

186 Infectious contacts

Infectious individuals are assumed to make $\hat{\kappa}$ effective contacts each time period; 187 where effective contacts are those that are sufficiently close and of a sufficiently 188 long duration to constitute a "risk of transmission." This rate is either a con-189 stant κ_0 , or in stochastic implementations drawn from a Poisson distribution 190 with mean κ_0 , or in adaptive formulations (e.g., under social distancing be-191 haviour) is a function of the severity of the ongoing outbreak. We also assume at 192 time t that under a random contact process, proportion $\frac{\hat{\kappa}(t)N_{\rm S}(t)}{N_0 - N_{\rm D}(t)}$ and $\frac{\hat{\kappa}(t)N_{\rm A}(t)}{N_0 - N_{\rm D}(t)}$ of these contacts will respectively be with susceptible and with uniquely identified agents, although only $\frac{\hat{\kappa}(t)(N_{\rm A}(t) - N_{\rm E}(t) - N_{\rm I}(t))}{N_0 - N_{\rm D}(t)}$ of those will be susceptible to infection with a new strain or projection with the 193 194 195 infection with a new strain or reinfection with the same strain. 196

In the adaptive case, we assume $\kappa(t)$ decreases from κ_0 as the proportion of infectious individuals, $N_{\rm I}(t)/(N_0 - N_{\rm D}(t))$, increases such that $\kappa(t) = \kappa_0/2$ when $N_{\rm I}(t)/(N_0 - N_{\rm D}(t)) = p_{\rm I}^{\rm half}$. For convenience of implementation, however, we define the following "switching" (as apposed to hyperbolic) function

$$\kappa(t) = \begin{cases} \frac{\kappa_0}{1 + \left(\frac{N_{\rm I}(t)}{N_0 - N_{\rm D}(t)} / p_{\rm I}^{\rm half}\right)^2} & \text{when } p_{\rm I}^{\rm half} > 0\\ \kappa_0 & \text{when } p_{\rm I}^{\rm half} = 0 \end{cases}$$
(A.10)

even though, from a continuity point of view, the top part of this expression implies that $\kappa(t) \to 0$ at $p_{\rm I}^{\rm half} \to \infty$.

203 Probability of infection

In deriving a probability $\pi_{ih,j\ell}^{\inf}$ of an agent A_h being infected with strain ℓ by and agent A_i who is infectious with major strain j, we concatenate (i.e., multiply together) several process, each of which involves nominal constants. Thus, in all but one of these processes, the scaling of these constants can be normalized and given a relative set of values across strains though one set of Submitted to PNAS

constants though relative, will ultimately all be scaled by fitting the model to 209 real data. In our treatment below, constants associated with shedding and per-210 sistence will be scaled while those associated with within-host replication will be 211 kept unscaled to be ultimately fitted to data. In particular, the parameters β_i 212 associated with pathogen transmission (i.e., from contact to the start of within 213 host replication—see Fig. 1) will be scaled by fitting to epidemiological data, 214 while the relative values for the different strains regarding pathogen shedding 215 and environmental persistence can be fitted to experimental data collect to set 216 values of these processes when considered on their own. 217

218

Pathogen shedding. We assume that shedding is affected by the immune state 219 of the infector A_i and thus posit the shedding rates below for this individual 220 when its major infectious strain is j. In general, we have a matrix of shedding 221 rates $\zeta_{i\ell}$ before accounting for immunity and cross immunity that is specific to 222 agent A_i . Immunity and cross-immunity act to reduce shedding rates through 223 functions $\phi_{ii}(t) \in [0,1]$ that are computed in terms of A_i's waning functions 224 ω_{im} with respect to strain m and a matrix of cross-immunity values c_{jm} that 225 have been normalized so that $c_{jj} = 1$ for $j = 0, ..., 2^J - 1$ and $c_{jm} \in [0, 1]$ for $j, m = 0, ..., 2^J - 1$. Specifically, we define agent-specific *immunity modifying* 226 227 functions 228

$$\phi_{ij}(t) = \prod_{m=0}^{2^J - 1} \left(1 - c_{mj} \omega_{im}(t) \right)$$
(A.11)

²²⁹ and assume that the shedding rates can be expressed as

$$\zeta_{ij\ell}(t) = \bar{\zeta}_{j\ell}\phi_{i\ell} \qquad \ell = 0, ..., 2^J - 1$$
 (A.12)

Environmental persistence. The persistence of pathogens in the environment 230 are known to be impacted by humidity, temperature, airflow, and the surface 231 properties of fomites [57]. This, and other factors relating the effects of weather 232 on contact rates and efficacy, may result in overall pathogen transmission having 233 a seasonal component to it [58]. In particular, viral persistence indoors may 234 be much greater than outdoors, with a greater proportion of indoor contacts 235 taking place during cold or wet weather. Thus the most appropriate place 236 to introduce seasonal effects into epidemic processes is through contact rates 237 and environmental persistence cycling over time with a period of one year (or 238 even half-a-year if two comparatively spaced rainy seasons occur, as in some 239 in tropical locations [59]) and an amplitude obtained by fitting parameters to 240 data. Thus, in our model, we introduce constants $\bar{\eta}_{\ell}, \delta \in (0, 1), k$ (appropriately 241 scaled, depending on the units of time) and θ and assume that 242

$$\eta_{\ell}(t) = \bar{\eta}_{\ell} \left(1 + \delta \sin\left(\frac{2\pi t}{k} + \theta\right) \right) \qquad \ell = 0, \dots, 2^{J} - 1 \tag{A.13}$$

The case $\delta = 0$ corresponds to constant values $\eta_{\ell}(t) = \bar{\eta}_{\ell}$ for all t, while if $\delta = 1$ we get the largest possible fluctuation between 0 and $2\bar{\eta}_{\ell}$. The constant krelates to the time units so we get one cycle per year, and θ shifts the cycle to set the points in time at which the maximum and minimum values of $\eta_{\ell}(t)$ occur. Submitted to PNAS

Strain transmission. In the context of a standardized dose (which will be modified by multiplying the strain *effective contact* and transmission by both pathogen shedding and environmental persistence functions), the differential rates of strain transmission, which we denote by $\beta_{h\ell}$, will depend on a constant strain transmission rate parameter $\bar{\beta}_{\ell}$ modified by a function that represents the immune state of the infectee at time t: viz., recalling Eq. A.11

$$\beta_{h\ell}(t) = \bar{\beta}_{\ell} \phi_{h\ell}(t), \quad \ell = 0, ..., 2^J - 1$$
 (A.14)

²⁵⁴ Probability of infection. Using a competing rates formulation [60] to compute ²⁵⁵ the probability of infection as a concatenation of the process of infector shedding ²⁵⁶ (ζ), environmental persistence (η) and transmission rates (β), we obtain

$$\pi_{ih,j\ell}^{\inf}(t) = \frac{\zeta_{ij\ell}(t)\eta_{\ell}(t)\beta_{h\ell}(t)}{\sum_{m=0}^{2^{J}-1}\zeta_{ijm}(t)\eta_{m}(t)\beta_{hm}(t)} \left(1 - e^{-\zeta_{ij\ell}(t)\eta_{\ell}(t)\beta_{h\ell}(t)}\right), \quad \ell = 0, ..., 2^{J} - 1$$
(A.15)

257 Within-host processes

If after receiving an initial infectious dose of pathogen, an individual is infected primarily with strain ℓ , then we expect this strain to dominate unless intrinsic mutational processes are high (which is not the case for COVID-19) or the individual has some immunity to this dominant strain. In the latter case the situation is ripe for an "escape mutation," that is one that evades the immune system, to arise.

If we nominally set the relative rate at which an individual invaded by strain 264 ℓ has an infection dominated by strain ℓ (i.e., ℓ in the terminology of [61] is 265 the major strain of the infection) to be $(1 - \mu)$, then the probability that one 266 of the other strains $\ell' \neq \ell$ (in the case of COVID we assume that $\mu > 0$ is 267 very close to 0—e.g. of order 10^{-3} to 10^{-6} —while for viruses lacking error 268 correcting machinery it can be considerably larger and of the order 10^{-1}). We 269 can partition the latter probability according to a set of comparative strain 270 within-host replication rates $\lambda_{\ell'}$, each moderated by its immune state function 271 $\phi_{h\ell'}$ and a normalizing factor $\frac{1}{\sum_{\forall m \neq \ell} \lambda_m \phi_{hm}}$ to obtain 272

$$\pi_{h\ell\ell'}^{\mathrm{inv}}(t) = \begin{cases} 1-\mu & \text{for } \ell' = \ell \\ \mu \left(\frac{\lambda_{\ell'}\phi_{h\ell'}}{\sum_{\forall m \neq l} \lambda_m \phi_{hm}}\right) & \text{for } \ell' \neq \ell \end{cases}$$
(A.16)

273 Pathogen progression equations

Probability that infector A_i with major strain j will result in infectee A_h express ℓ' as its major strain is

$$\pi_{ih,j\ell'}(t) = \sum_{\ell=0}^{2^J - 1} \pi_{ih,j\ell}^{\inf}(t) \pi_{h\ell\ell'}^{\inf}(t), \quad \ell = 0, ..., 2^J - 1$$
(A.17)

Submitted to PNAS

276 Single strain case

In the single strain case (J = 0), the waning immunity equation Eq. A.6 reduces to (dropping the redundant index j = 0, and noting that the existence of a value τ_i implies A_i has been infected at time τ_i in the past)

$$\omega_{i}(t) = \begin{cases} 0 & \text{if } \mathbf{A}_{i} \text{ has never been infected} \\ \frac{1}{1 + \left((t - \tau_{i} - \sigma_{\mathrm{I}} - \sigma_{\mathrm{E}})/t^{\mathrm{half}} \right)^{\sigma}} & \text{if } t \geq \tau_{i} + \sigma_{\mathrm{I}} + \sigma_{\mathrm{E}} \\ 1 & \text{if } t < \tau_{i} + \sigma_{\mathrm{I}} + \sigma_{\mathrm{E}} \end{cases}$$
(A.18)

and the modifying immunity functions ϕ_{ij} (Eq. A.11) collapse to 1, which implies that the pathogen shedding functions $\bar{\zeta}_{i\ell}$ (Eq. A.12) collapse to 1. Without loss of generality, we can also assume that single strain value $\eta = 1$ in Eq. A.13, which implies that the probability of infection (Eq. A.15) reduces to

$$\pi_{ih}^{\inf}(t) = 1 - e^{-\bar{\beta}(1 - \omega_h(t))} \tag{A.19}$$

Further, since in the single strain case there are no mutations to consider, it follows from Eq. A.16 that $\pi_{h\ell\ell'}^{\text{inv}}(t) = 1$ for all h and we finally have that $\pi_{ih}(t) = \pi_{ih}^{\text{inf}}(t) = 1 - e^{-\bar{\beta}(1-\omega_h(t))}$ (Eq. A.17) for all h.

287 Simulation algorithm

1. Parameters selected at the start of a simulation

289 (a 290 291 292) N_0 : Number of individuals in the population. Assumed to be fixed over time (i.e., the population is closed), but partitioned into sets S , A and D with respectively $N_{\rm S}(t)$, $N_{\rm A}(t)$ and $N_{\rm D}(t)$ individuals in each set and satisfying Eq. A.1.
293 (b 294) J: The \log_2 of the number of possible strains indexed by $j = 0, \cdots, 2^J - 1$
295 (C 296 297) $\bar{\beta}_j$: Strain dependent transmission parameters (the process between contact and the start of strain replication and nominally equivalent to transmission in SEIR models—see Fig. 1) for pathogen strain j
298 (d 299) t_j^{half} : The time it takes for immunity to strain j to have waned by half.
300 (e 301 302) $\sigma_{\mathrm{E}_{j}}$: The time it takes from initial infection for an infected individual to become more likely to become infectious than remain infected without being infectious.
303 (f 304 305) σ_{I_j} : The additional time it takes beyond σ_{E_j} for an infectious individual to more likely transition beyond being infectious than remain infectious.
306 (g 307 308) p_{α_j} : The proportion of individuals leaving the infectious category that die, which implies that $1 - p_{\alpha_j}$ is the proportion that become immune.
309 2. Ini	tialization

Submitted to PNAS

310

311

312

314

315

316

317

318

319

320

321

322

323

324

325

326 327

328

329

330

331

332

- (a) Set up pathogen list (see Eq. A.2)
- (b) Initialize the simulation by setting t = 0 and creating the agent list $\mathbf{A}(0)$ one infectious and $N_0 1$ susceptible agents.
- 313 3. Time *t*: vaccination loop.
 - (a) Carry out the vaccination process before going into the rest of the loops with the updated S and A sets after the vaccinations.
 - 4. **Time** *t*: **contact loop.** Set up contacts for the current round of encounters at time *t* (i.e., the inner agent-driven contact loop within the outer time-driven loop) and tag for outer loop update of disease status, as follows:
 - (a) Numbers in various sets and associated index sets. Identify the number of individuals $N_{\rm S}(t)$, $N_{\rm A}(t)$ and $N_{\rm D}(t)$ in sets **S**, **A** and **D** at time t respectively, as well as the number of exposed (but not yet infectious) agents $N_{\rm E}(t)$, infectious agents $N_{\rm I}(t)$ and identified non-infected agents $N_{\rm A_S}(t) = N_{\rm A}(t) N_{\rm I}(t) N_{\rm E}(t)$. Break down the infectious agents tally into the number of agents $N_{\rm I_j}$ infectious with strain $j = 0, 1, ..., 2^J 1$. We will also need the index sets $\mathbb{I}_{\rm A_S}$ and $\mathbb{I}_{\rm I_j}(t), j = 0, ..., 2^J 1$ at time t.
 - (b) Infectious contacts with each group. The rate at which any individual contacts other individuals per unit time is given by the contact rate parameter $\kappa > 0$. Assuming random contact events over one unit of time, the actual number of individuals that agent A_i contacts at time t is then given by

$$\hat{\kappa}_i(t) \sim \text{POISSON}[\text{mean} = \kappa(t)]$$

Of these, proportions

and

$$\pi_{iS} = \frac{N_{S}(t)}{N_{0} - N_{D}(t)} \tag{A.20}$$

$$\pi_{iA} = \frac{N_A(t) - N_I(t) - N_E(t)}{N_0 - N_D(t)}$$
(A.21)

are expected to come from susceptibles in the sets $\mathbf{S}(t)$ and $\mathbf{A}_{\mathrm{S}}(t)$ (see Eq. A.5) respectively. Thus the actual number of contacts in set $\mathbf{S}(t)$, $\mathbf{A}_{\mathrm{S}}(t)$, and $\mathbf{E}(t) \cup \mathbf{I}(t)$ are

We note that only $\hat{N}_{i}^{S}(t)$ and $\hat{N}_{i}^{A_{S}}(t)$ are of interest because individual in states E and I cannot be reinfected. Also, we make the assumption below that the first infection that an individual in set **A** contracts in this contact loop, is the one that counts (i.e., there will

)

Submitted to PNAS

337

338

339

340

341

342

343

344

345

347

348

349

350

351

352

353

354

355

356

357

359

360

361

362

363

364

365

366

367

be no simultaneously infections with multiple strains). Finally, since contacting individuals is tantamount to sampling with replacement, the number of unique contacts (i.e., all multiple contacts are counted as a single contact) that agent A_i has with individuals in the set **S** is $\hat{N}_i^{\rm S}(t)$ reduced by excluding multiple contacts (which under a random contact model is a negative exponential correction) to obtain

$$N_i^{\mathrm{S*}}(t) = \min\left\{\hat{N}_i^{\mathrm{S}}(t), \mathtt{Binomial}\left[\hat{\kappa}_i(t), e^{-\hat{\kappa}_i(t)/\hat{N}_i^{\mathrm{S}}(t)}\right]\right\}$$
(A.23)

Thus if $\hat{\kappa}_i(t) \ll \hat{N}_i^{\mathrm{S}}(t)$, $N_i^{\mathrm{S}*}(t)$ is expected to be very close to the upper value $\hat{\kappa}_i(t)$. On the other hand, if $\hat{\kappa}_i(t) \approx \hat{N}_i^{\mathrm{S}}(t)$, then $N_i^{\mathrm{S}*}(t)$ is expected to be around $\hat{\kappa}_i(t)/e \approx 0.37\hat{\kappa}_i(t)$. Additionally, after dealing with each agent *i* reduce in the size of $N_{\mathrm{S}}(t)$ to take account of those agents that had been infected by agent A_i and had now entered the ranks of the set **A**.

(c) Identify all infectious agents and their pathogens strains. Among all agents in the set $\mathbf{A}(t)$ (Eq. A.4), identify those that have an infectious strain I_j for some $j = 0, \dots, 2^J - 1$. Thus, if the number of infectious agents with infectious strain j is $N_{I_j(t)}$ then consider the set

$$\mathbf{I}_{j}(t) = \{\mathbf{A}_{i_{1}}^{j}(t), \mathbf{A}_{i_{2}}^{j}(t), \dots, \mathbf{A}_{N_{1}}^{j}(t)\}$$

with index set

$$\mathbb{I}_{\mathbf{I}_j}(t) = \{i_{1_j}, \cdots, i_{N_{\mathbf{I}_j}(t)}\}$$

Initially, most of these sets will be empty, but will fill in over time.

(d) Susceptible contacts. The probability that an agent A_i with a strain j major infection infects a susceptible (nominally denoted by individuals of type A_0) who then becomes infectious with dominant strain ℓ' is given by the probability $\pi_{i0,j\ell'}$ computed in Eq. A.17, which itself relies on expressions Eq. A.10-A.16. The actual number of individuals in the set **S** will make effective contact with one more infectious individuals is $N_i^{\text{S}*}(t)$ obtained using Eq. A.23. Thus, from a multinomial drawing, we can now generate the number of newly exposed individuals, $N_{0\ell'}^{\text{E}+}(t+1)$ (the "+" is used to denote these are newly added and the "0" that they are coming from the set **S**), with major strain ℓ' at time t + 1, have been infected by agent A_i with major pathogen strain j on the time interval [t, t+1):

$$(\hat{N}_{00}^{\text{E+}}(t), \cdots, \hat{N}_{02^{J}-1}^{\text{E+}}(t)) \sim$$

$$\text{Multinomial} \left[N_{i}^{\text{S*}}(t); \pi_{i0,j0}(t), \cdots, \pi_{i0,j\,2^{J}-1}(t) \right]$$

$$(A.24)$$

These individuals will be used to update list of currently infected individuals in the sets $\mathbf{A}_{\mathrm{E}_j}$, $j = 0, ..., 2^J - 1$ at time t+1, which is computed in the outer loop computation, as presented below. We also note that the probabilities in the above multinomial add to less than 1, so that at the end of the drawing a proportion of the individuals $N_i^{\mathrm{S*}}(t)$ remain uninfected.

Submitted to PNAS

368

369

370

372

373

374

375

376

377

378

379

381

382

383

384

385

386

387

388

389

390

391

392

(e) Agent contacts. The number of agents $\hat{N}_i^{A_S}(t) \in \mathbb{I}_{A \setminus (E \cup I)}$ that come into contact with agent A_i over the interval (t, t + 1) is given by Eq. A.22. This number is drawn from the set $\mathbb{I}_{A \setminus (E \cup I)}$ with replacement and the following multinomial computation is used to determine how to update agent A_h at time t + 1 when coming into contact with agent A_i on the interval (t, t + 1) using the probabilities of transmission given in Eq. A.17. Specifically, agent A_h will become infected with major strain ℓ' at time t + 1 is determined by the multinomial drawing

$$A_h \in \mathbf{A}_{\mathrm{E}_j} \text{ for some } j \sim \mathtt{Multinomial} \begin{bmatrix} 1; \pi_{ih,j0}(t), \cdots, \pi_{ih,j\,2^J-1}(t) \end{bmatrix}$$
(A.25)

We note here that since the agents A_h , $h \in \mathbb{I}_{A \setminus (E \cup I)}$ are drawn with replacement as the computation proceeds and the agents A_i , $i \in \mathbb{I}$ are cycled through, if a previously drawn A_h is drawn again, but has already been infected in the current round then we ignore the latest event, but keep the previous infection event intact. To obviate bias in this procedure, we need cycle through the agents A_i , $i \in \mathbb{I}$ at random rather than in numerical order.

5. Time *t*: disease progression loop.

(a) Individuals in \mathbf{A}_{E} at time t. An individual $A_i \in \mathbf{A}_{\mathrm{E}}$ at time t and in state $\mathbf{E}_j(t, \tau_i), j = 0, ..., 2^J - 1$, becomes either an individual in state $\mathbf{E}_j(t+1, \tau_i)$ with probability

$$\pi_{\mathbf{E}_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{\mathbf{E}_j}}\right)^4} \tag{A.26}$$

Getz et al., June 7, 2021

or transfers to state $I_j(t+1, \tau_i)$ with probability $(1 - \pi_{E_j}(t))$ thereby entering class A_I at time t + 1.

(b) Individuals in \mathbf{A}_{I} at time t. An individual $A_i \in \mathbf{A}_{\mathrm{I}}$ at time t and in state $I_j(t, \tau_i), j = 0, ..., 2^J - 1$, becomes either an individual in state $I_j(t+1, \tau_i)$ with probability

$$\pi_{I_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{E_j} + \sigma_{I_j}}\right)^4}$$
(A.27)

or leaves the set $I_j(t + 1, \tau_i)$ with probability $(1 - \pi_{I_j}(t))$. In this latter case, the individual either dies with probability p_{α_j} or enters the state $V_j(t+1,\tau_i)$ at time t+1 with probability $1 - p_{\alpha_j}$ The total number of individuals dying over the interval [t,t+1) is noted as having a value $\Delta N_D(t)$.

6. Time t + 1: outer loop update. The outer loop records all the events that took place in the contact and disease progression loops and updates the agents state at the next time step. It also updates all other states as follows.

Submitted to PNAS

(a) Individuals in \mathbf{A}_{S} at time t. For the $N_{\mathrm{S}}(t)$ individuals in \mathbf{A}_{S} at time t, we have $N_{0i}^{\mathrm{E}+}(t)$ enter set $\mathbf{A}_{\mathrm{E}_{i}}(t+1)$ and we update

$$N_{\rm S}(t+1) = N_{\rm S}(t) - \sum_{j=0}^{2J-1} N_{0j}^{\rm E+}(t)$$

where Eq. A.23 ensures that $N_{\rm S}(t+1) \ge 0$

- (b) Individuals in \mathbf{A}_{S} that are infected again over [t, t+1). These individuals can become reinfected as calculated in the contact loop. Those that become reinfected with strain $j, j = 0, ..., 2^{J} - 1$ enter state $\mathbf{E}_{j}(t+1, t+1)$ at time t+1.
- (c) Updating the immunity of individuals in \mathbf{A}_{S} . Every individual within \mathbf{A}_{S} at time t must have its immunity status updated so that for $j = 0, ..., 2^{J} 1$, if \mathbf{A}_{i} is in state $V_{j}(t, \tau_{ij})$ at time t then it transfers to state $V_{j}(t+1, \tau_{ij})$ at time t+1, even if reinfected, as in b.) above.
- (d) Transfer from **S** to **A**. The $\hat{N}_{0j}^{\text{E}}(t)$ computed in Eq. A.24 become newly listed members of the set **A** by entering state $\mathbf{E}_j(t+1,t+1)$, $j = 0, ..., 2^J - 1$. This involves updating the equations for $N_{\text{S}}(t)$ and $N_{\text{A}}(t)$, including taking account of the number of individuals $\Delta N_{\text{D}}(t)$ that died from the disease in the immediate time period, i.e.:

$$N_{\rm S}(t+1) = N_{\rm S}(t) - \sum_{j=0}^{2^J - 1} \hat{N}_{0j}^{\rm E}(t)$$

$$N_{\rm A}(t+1) = N_{\rm A}(t) + \sum_{j=0}^{2^J - 1} \hat{N}_{0j}^{\rm E}(t) - \Delta N_{\rm D}(t) \qquad (A.28)$$

$$N_{\rm D}(t+1) = N_{\rm D}(t) + \Delta N_{\rm D}(t)$$

(e) Along with input parameter values $t_{\text{vac_on}} \geq 0$, $t_{\text{vac_off}}$ and $p_v \in [0, 0.1]$, we also need to specify the valency of the vaccination by selecting 1 to 4 numbers that take on values $0, ..., 2^J - 1$ (if more valencies are needed than 4, then the platform needs to be modified accordingly). We also need specify whether N_{select} will just be individuals in the set $\mathbf{S}(t)$ ($N_{\text{select}} = N_{\text{S}}$) or will be any individual other than those in the set $\mathbf{A}_{\text{I}}(t)$ ($N_{\text{select}} = N_{\text{S}} + N_{\text{A}} - N_{\text{I}}$).

In Algorithm 1 we summarise the steps of the simulation algorithm, as described in this section. On the right we report the name and numbering of the subsections while in the for loops we list the various steps respecting the item letters. Note that technical steps not explicitly described in the text (e.g. store updates, store set progression) do not present letters or numbers. The time set is defined with T while to describe temporal progression of set \mathbf{S}, \mathbf{A} and \mathbf{D} we use the symbols $\mathcal{S}, \mathcal{A}, \mathcal{D}$ respectively.

430 Estimation of R_0 .

In a continuous time, SEIR model, when κ is folded into an all encompassing frequency-dependent transmission rate parameter $\beta_{\kappa} = \beta \kappa > 0$ (i.e.,

41

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

402

Getz et al., June 7, 2021

Algorithm 1. Summany of simulation algorithm	
Algorithm 1: Summary of simulation algorithm	
input $N_0, J, \bar{\beta}_j, t_j^{\text{half}}, \sigma_{\mathrm{E}_j}, \sigma_{\mathrm{I}_j}, p_{\alpha_j}, j = 0,, 2^J - 1$ // 1)	
parameters	
$\{(\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j}; \zeta_{jm} \text{ and } c_{jm} \text{ for } m = 0,, 2^J - 1)$ // 2a) pathogen	
$j = 0,, 2^J - 1$ // list	
$t = 0, N_{\rm I}(0) = 1, N_{\rm S}(0) = N_0 - 1$ // 2b) initialization	
for t in T do	
if $N_{\rm I} > 0$ then	
$ \begin{bmatrix} \text{for } agent in \mathbf{S} \cup (\mathbf{A} \setminus \mathbf{I}) \text{ do} & // 3 \end{bmatrix} \text{ vaccination loop} \\ \begin{bmatrix} 3a \end{bmatrix} \text{ Vaccination process} \\ \text{Update } N_{\mathbf{S}} \text{ and } N_{\mathbf{A}} \end{bmatrix} $	
for agent in I do // 4) contact loop 4a) Numbers in various sets and associated index sets 4b) Infectious contacts with each group 4c) Identify all infectious agents and their pathogens strains 4d) Susceptible contacts 4e) Agent contacts Store updates	
for agent in E do // 5a) disease progression loop $\begin{bmatrix} 5a \end{bmatrix}$ Individuals in A_E at time t Store updates	
for agent in I do// 5b) disease progression loop $5b$) Individuals in A_I at time tStore updates	
$ \begin{array}{ c c c c c } Updates from loops 4), 5a) and 5b) \\ \hline 6a) Individuals in \mathbf{A}_{\mathrm{S}} at time t // 6) updates in outer loop 6b) Individuals in \mathbf{A}_{\mathrm{S}} that are infected again over [t, t+1) 6c) Updating the immunity of individuals in \mathbf{A}_{\mathrm{S}} 6d) Transfer from \mathbf{S} to \mathbf{A} 6e) Specify the valency of the vaccination \mathcal{S}[t] \leftarrow \mathbf{S}(t) // store set progression \mathcal{A}[t] \leftarrow \mathbf{A}(t) \mathcal{D}[t] \leftarrow \mathbf{D}(t) \end{array} $	
$\mathbf{return}\;\mathcal{S},\mathcal{A},\mathcal{D}$	

Submitted to PNAS

total is transmission given by $\frac{\beta SI}{N}$ [49, 50]), $\gamma > 0$ is the transition rate from E to I and $\rho > 0$ is recovery rate from I to R, then R_0 corresponds to [62]

$$R_0 = \frac{\beta_\kappa}{\gamma + \rho} \tag{A.29}$$

436 **B** J-RAMP Details

437 General description

The J-RAMP design augments a desktop simulation platform with several novel features that increase flexibility and expressiveness, and promote experimentation and interoperability with other platforms. These include an API ("application programming interface") fully supporting remote operation and direct retrieval of data for external processing on other platforms, such as Python, Javascript or the R statistical platform. The API can also be accessed by an onboard scripting interface that uses the Nashorn Javascript engine.

Additionally, using a novel design, elements of the internal algorithm are exposed for possible reprogramming in a secure fashion that will not damage the overall system. These runtime alternative modules (RAMs) may also be controlled from the API to facilitate selective algorithm redefinition during the run of the simulation.

Use of the J-RAMP features require some experience with scripting and/or
Java coding, however the resulting modifications to the algorithm can be of great
significance. The RAM platform is implemented to support program redefinition
with no risk to damaging the underlying code base. It should be accessible to
anyone with moderate scripting experience.

A major goal of the J-RAMP project is to pre-package these functionalities so
that they can be readily deployed as part of simulation system design. This goal
has been partially realized with respect to the RAM platform: annotations can
be added to the simulator's source code that direct the automatic generation of
Java code to integrate into the simulations's source and provide the functionality.
The following discussion assumes some familiarity with script or program
development.

462 Runtime alternative modules

Figure B.1 shows the RAM redefinition frame. The available RAMs appear as 463 radio buttons along the bottom of the frame. Each RAM is a set of options 464 for defining a relatively short Java method implementing some key aspect of 465 the simulation algorithm. For example, included in this simulation are the 466 implementation for cross immunity given in Eq. 1; the implementation for β 467 given in Eq. A.14; and the implementation for ϕ given in Eq. A.11; etc. Each 468 RAM initially contains only a single option, Option 0, the default, internally 469 defined implementation. Option 0 cannot be edited and appears for reference 470 purposes only. 47

Additional options may be added to each RAM containing code redefining the method. Two editor panes and one console pane are stacked in the frame

Submitted to PNAS




Figure B.1: RAM frame shows the implementation of the nearest-neighbor crossimmunity formulation \mathbf{C} of Eq. 1 as the default. In the red-bordered insets are the cascading cross-immunity with escape mutation formulations of Eqs. A.7 and A.9. Note the radio-buttons are set to 0 in the main figure and to 1 and 2 in the insets. Also note the "+" button which allows for an unlimited number of alternatives to be set up using consecutive integer numbers for the new radio-buttons that appear and pertain to the selection of each alternative. Note at the bottom the list of functions that can be altered at runtime. The "load default" button on the upper left hand side allows the user, when starting a new alternative, to insert the default code (which is immutable in radio-button 0) as a starting point. The frame also documents a list of terms in the upper panel that can be used to build any function.

and display the code and output of the RAM. These panes show the content 474 associated with the currently selected RAM and option. The top editor pane 475 contains the code for the method being redefined. The second editor pane con-476 tains definitions of any new help functions required by the definition in the top 477 pane. The console pane contains messages and output that are useful during the 478 development of the option. For convenience, a "Load Default" button initializes 479 the editor to an editable version of the Option 0 default to use as a starting 480 point. 481

482 Figure B.1 shows the Option 0 default definition for the cross immunity

Submitted to PNAS

matrix function, as described by Eq. 1. Clicking the "+" button produced two
new options, which appear in the insets. These option implement the alternative
cascading cross immunity schemes presented in Eqs. A.7 and A.9. Option 2 code
appears below:

```
487 double crossImmune(int j, int k) {
488 if (l == j) return 1;
489 if (j < pathSize()/2 && l > pathSize()/2) return 0;
490 return Math.pow(Params.cImmune(), Tools.hdist(j, l));
491 }
```

⁴⁹² Note that we have substituted the function pathSize for a hard-coded value ⁴⁹³ of 63. pathSize returns the number of pathogens, allowing us to use this ⁴⁹⁴ formulation for any choice of entropy. Documentation for pathSize is at the ⁴⁹⁵ top of the window in the list of available help functions and parameters. There ⁴⁹⁶ is also more extensive documentation in a separate user guide (see Fig. B.2).

The platform duplicates a mini-development environment for building alter-497 native definitions. Once code has been entered the "Compile" button checks the legality of the code and makes it available for use at runtime. Legally com-499 piled code will produce a "Compilation Successful" message. Errors will appear 500 with line numbers if they occur. Once the code is legal, the "Test" button can 501 be used with actual parameters entered into the small text fields to determine correctness of the code. It is also possible to include print and println state-503 ments in the code during development to further check correctness. Output 504 from print statements will appear in the bottom console window. The entire 505 RAM set can be saved and will reappear during subsequent launches of the 506 simulator platform. 507

To use an alternate RAM definition at runtime simply select the desired option. (Selected options will be restored from a saved RAM set during subsequent launches.) The system will compile any uncompiled code the first time it is accessed. If an error occurs during a runtime compilation an alert will notify the user that the system is returning to the default definition of that RAM. At no time is the internal logic of the program overridden.

Finally, RAM option selection is part of the API described in the next section. This means that a script may run a simulation selecting different options at different points in time, using logic that considers the state of the model. For example, such an adaptive protocol might be appropriate for determining the contact rate κ .

⁵¹⁹ Application programming interface

The API is a simple bytecode¹ called BPL (Blackbox Programming Language) that addresses all available user interactions with the simulator. Instructions fall into three categories: parameter assignment and retrieval; simulator operation; and data retrieval. A complete list of instructions is shown in Fig. B.3. Instructions are comprised of opcodes (e.g., reset, step, get) followed by 0 or more arguments. Every BPL operation returns a result, even if empty, for

 $^{^{1}}$ a *bytecode* is computer source code that is processed immediately by a program, usually referred to as an interpreter or virtual machine.

Getz et al., June 7, 2021

Submitted to PNAS

J-RAMP SEIVD IBM A-Mod Guide

rms wgetz

May 2021

 ω (Equation 9)

$$\omega_{ij}(t) = \begin{cases} 0 & \text{if } V_j \text{ is null} \\ \frac{1}{1 + \left((t - \tau_{ij} - \sigma_{\mathrm{I}} - \sigma_{\mathrm{E}})/t_j^{\mathrm{half}} \right)^{\sigma}} & \text{if } t \ge \tau_{ij} + \sigma_{\mathrm{I}} + \sigma_{\mathrm{E}} \\ 1 & \text{if } t < \tau_{ij} + \sigma_{\mathrm{I}} + \sigma_{\mathrm{E}} \end{cases}$$

 Code

```
double omega(int i, int j)
{
  if (i == 0) return 0.0;
                                    // Special case; A_0 never infected
  InfectedAgentState astate = getStateOf(i, j);
  if (astate == null || !(astate instanceof V)) return 0.0;
  double tau = tau(i,j);
  double sigI = sigmaI(j);
  double sigE = sigmaE(j);
  double timeSinceInfect = tau + sigI + sigE;
  if (time() <= timeSinceInfect) return 1.0;</pre>
  return 1/(1 + Math.pow((time() - timeSinceInfect)/tHalf(j), Params.sigma()));
}
Notes
 astate = getStateOf(i,j)
                                       astate is assigned to a Java InfectedAgentState
                                       object for agent i with respect to pathogen j.
                                       InfectedAgentState objects can either be state E, I, V
                                       or null (the latter for never-infected or dead agents.)
 astate == null || !(astate == V)
                                       astate is something other than state V.
 tau(i,j)
                                       = \tau_{ij}.
 sigmaI(j)
                                       = \sigma_{I}.
 sigmaE(j)
                                       = \sigma_{\rm E}
                                       =\tau_j^{\tilde{h}alf}
 tHalf(j)
 time()
                                       = t.
 Params.sigma()
                                       = \sigma
```

Figure B.2: A description from our User Guide of the immunity waning function ω .

synchronization purposes. A string consisting of a sequence of opcodes and
arguments may be submitted to the BPL interpreter, an example of which is
shown in the notes in Fig. B.3.

529

```
Parameter assignment and retrieval. Every user-configurable element (in-
530
    cluding random number generator seeds) is addressed from BPL using a unique
531
    three-letter "airport code" (see Table. B1). Additionally, pathogens are ad-
532
    dressed by their id number (0 to 2^{J} - 1) and agent states using identifiers S, E,
533
    I, V, DI+ and DD (the latter two represent \Delta I and \Delta D, respectively). RAM
534
    options are addressed in setOption and getOption using the name of the RAM
535
    (e.g., "crossImmune"). Get and set operations can be used on each of these with
536
    the exception of ENT (strain entropy), which is read-only.
537
```

538

Submitted to PNAS

Simulator operation. Simulation runs begin by executing the BPL reset
instruction, followed by step, run_for or run. The BPL interpreter operates
synchronously with the simulator by waiting to process subsequent commands
during a simulation run. Operational instructions can be interspersed with parameter set/get or data retrieval to use in runtime decision-making. Note that
the reset operation restores the simulator to its state at the time of the last
reset, so that no parameter changes made during a run are persistent.

546

547 Data retrieval Operations to obtain the current population in each state, and 548 to retrieve the runtime population history of each state and pathogen are also 549 included. These can be easily transformed into R data frames, for example, for 550 further analysis.

551

Scripting can be deployed using either one of the two on-board script interpreter interfaces, or remotely from another platform using drivers provided with the simulator. The remote drivers use an operating system channel called *named pipes* or *fifos* that are part of all MacOS, Windows, Linux, and other UnixTM-based systems.

On our main dashboard, we provide two scripting windows that are opened using the "S On" and "JS On" buttons (see button second and third from left at 558 bottom of Fig. 2A). The former allows the user to write simulation driver scripts 559 directly as command strings. (The commands listed in Fig. B.3 are accessed 560 by pressing the "Command Reference" button in the "S On" window.) This 561 window is used primarily to test and monitor scripts intended to be deployed on 562 a remote platform. The JS window contains a Nashorn Javascript interpreter 563 enhanced to accept and execute BPL operations. Scripts can developed, saved, 564 and used to drive the simulator from this interpreter. For example, Fig. B.4, lists 565 the code used to implement the adaptive vaccination programs. The SEIV object 566 referenced in this code contains methods corresponding to the BPL operations 567 detailed in Fig. B.3. 568

Name	Math	Code	Name	Math	\mathbf{Code}					
Epidemic codes										
% mortality env. persist. median latent period population size mutation rate cross immunity seas. trans. peturb seas. trans. period	$p_lpha \ \eta \ \sigma_{ m E} \ N_0 \ \mu \ c \ \delta \ k \ J$	MOR PST MLP POP MUR CIM STP PER ENT	transmission within-host replication median infectious period contact rate abruptness of waning waning half-life seas. trans. shift adap. contact param. abaddian meta	$egin{array}{c} eta \ \lambda \ \sigma_{\mathrm{I}} \ ar{\kappa} \ \sigma \ t^{\mathrm{half}} \ heta \ p_{\mathrm{I}_{\overrightarrow{\kappa}}}^{\mathrm{half}} \end{array}$	XMT INV MIP CPT AOW WHA STS IPC SHD					
strain entropy	J		shedding rate	ζ	SHD					
enable vaccination strain valency type vaccinate susc. only vaccinate non-vacc.	VA#, #	VEN	vaccine on/off selection composition vaccinate non-infectious	$t_v^{ m on}/t_v^{ m off}$	VOO VCP NVI					

Table B1: Airport codes for parameter and variables used in the model algorithm

BPL Reference

Commands

reset	Resets simulation with initial slider/switch values.
restart	Resets simulation with current slider/switch values.
run_for T	Run the simulation from the current time for $\boldsymbol{\tau}$ steps.
run	Run the simulation for the number of steps set by the last run_for command.
step	Single-step the simulation one time unit.
get time	Returns current simulation time.
getLimit XXX	Returns lower and upper values of limit control labeled xxx on separate lines.
getPath XXX id	Returns value of parameter xxx in pathogen id.
get XXX	Returns value of non-limit control labeled xxx.
setLimit XXX lo hi	Sets the limit control XXX to limits lo hi.
setPath XXX id Y	Sets value of parameter xxx in pathogen id to Y.
set XXX Y	Sets value of non-limit control xxx to x.
pathPop id Z	<i>id</i> is a pathogen id and <i>z</i> must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the current population in state <i>z</i> with respect to pathogen <i>id</i> .
totPop Z	<i>z</i> must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the total population in state <i>z</i> .
timeTrail	Returns the array of timesteps for use in a table with other trail data.
pathTrail <i>id Z</i>	<i>id</i> is a pathogen id and <i>z</i> must be one of the agent state identifiers (S, E, I, V, DI+, DD). The population array for that pathogen and for that state over time is returned.
popTrail Z	<i>z</i> must be one of the agent state identifiers (S, E, I, V, DI+, DD). The array of the entire population over time for that state is returned.
sleep T	NMBPL processor sleeps for $\boldsymbol{\tau}$ milliseconds.
	(May be used for synchronization during longer simulations.)

Notes

- · Commands without explicit return do not return a value
- get and set use the 3-letter "airport codes" associated with each control
- Commands may be sequenced; e.g.

run_for 50 set XMT 1.5 run trail PATH I

will run for 50 timesteps, set the transmission paramter to 1.5, run for another 50, and return the 100 population values of I.

• Returned values are separated by newlines. When command sequences are sent remotely, left and right brackets (i.e. \[\ and \]\) followed by newlines enclose the sequence of returned values, even if the sequence is empty; e.g.,

[\n50\n100\n1000\n]

- When using trail: if embedded in a command sequence, this must be the only command that returns a value (since the array returned by each of them will be embedded in the set of answers returned by the command sequence.)
- Use the console to test command sequences before using them remotely.
- Changes to the FIFOs, if saved to Preferences, will reappear in subsequent uses. Multiple instances of Numerus
 can run concurrently using different FIFOs.
- Restart button restarts the FIFO configuration.

Figure B.3: The list of Blackbox Programming Language (BPL) commands that can be used to write a simulation driver script, using the three-letter "airport codes" listed in Table A1 to access the parameters and variables in our coded algorithm. This list of commands can be accessed using the "Command Reference" button at the bottom of the Scripting Window.

⁵⁶⁹ R Integration

As previously mentioned, the API supports remote control of the simulator from independent platforms using the operating system's indigenous *fifo* channels. Of particular interest is integration with the R statistical programming




Figure B.4: The JS scripting window accessed by selecting the "JS On" button in the main dashboard (see button second from left at bottom of Fig. 2A). The script shown here was used to execute the adaptive vaccination strategy discussed in the main text.

environment. An R-package called "seiv" acts as a driver by synchronously issuing BPL command strings and waiting for results. Consequently, a simulation
can be driven entirely from within the R platform, treating the simulator as a
"virtual package".

Fig. B.5 shows the code used to run the simulator multiple times with different random number generator seeds. Following each run, the time history of the population in the I, DI+ and DD states is extracted directly to an R data frame (without the need to save, for example, in a comma-separated list). At the end of the run sequence the data frame is used to build the plots shown in Fig. C.2.

R could be used in a more direct way by analyzing data at various points throughout a single run and adjusting parameters programmatically, similar to the adaptive vaccination strategy carried out in Javascript, only taking advantage of the R environment's powerful toolkit.






Figure B.5: Our SEIVD-IBM can be treated as an R-package called "seiv" and run as such in conjunction with other packages, such as ggplot2 and reshape to conduct multiple simulations and then carry out data and statistical analyses of the simulation results. The code shown here was used to produce the plots illustrated in Fig. C.2.

587 C Additional Figures

	N=10,	000	1	N=30,0	000				
Run seed	S fnl	V fnl	Total D	t fnl		S fnl	V fnl	Total D	t fnl
0	2135	7700	165	166		6574	22964	462	212
1	2234	7522	144	171		6431	23067	502	193
2	2252	7602	146	158		6516	23020	464	175
3	2174	7668	158	188		6568	22958	474	220
4	2154	7684	162	162		6345	23214	441	191
5	2127	7706	167	165		6520	22998	482	196
6	2166	7662	172	159		6604	22950	446	198
7	2280	7573	147	171		6282	23250	468	197
8	2254	7613	133	161		6339	23184	477	187
9	2153	7681	166	169		6529	23050	421	201
Mean	2193	7641	156	167		6471	23066	464	197
SD	56	61	13	9		114	112	23	13
Mean %	0.219	0.764	0.0156			0.216	0.769	0.0155	
SD %	0.006	0.006	0.0013			0.004	0.004	0.0008	

Figure C.1: The final sizes of the uninfected $(S(t_{\rm fnl}) \text{ individuals})$, infected $(V(t_{\rm fnl}) \text{ individuals})$ and dead $(D(t_{\rm fnl}) \text{ individuals})$ classes and the length of the epidemic $(t_{\rm fnl} \text{ days})$ are provided here, together with summary statistics, for 10 simulations (runtime seed ranges from 0 to 9) in each case when the initial population sizes are $N_0 = 10,000$ and $N_0 = 30000$ individuals respectively. The parameter values used are otherwise the same as those use to produce the simulation depicted in Fig. 2 in the main text.

Getz et al., June 7, 2021




Figure C.2: Plots of the mean (red) ± 1 standard deviation green and blue, the latter truncated at 0) of prevalence, incidence, and daily deaths for 100 runs (runtime seeds = 0,...,99) using the same parameter set used to produce the individual run (runtime seed = 0) depicted in Fig. 2 in the main text (also see Fig. C.1). These figures where produced by running our SEIVD-IBM J-RAMP as an R-package as described in Appendix B, with the code documented in Fig. B.5.




Figure C.3: If, together with our basic set of parameters (Table 1), we set $p_{\rm I}^{\rm half} = 0.005$ then the total number of individuals that have been infected (disease class V) at the end of one year is $10027/100,000 \approx 10\%$.

Getz et al., June 7, 2021

Strain	beta														
0	0.300	16	0.149	32	0.246	48	0.295	64	0.235	80	0.152	96	0.196	112	0.272
1	0.325	17	0.097	33	0.244	49	0.076	65	0.121	81	0.127	97	0.172	113	0.233
2	0.007	18	0.117	34	0.011	50	0.289	66	0.249	82	0.138	98	0.177	114	0.261
3	0.350	19	0.089	35	0.029	51	0.155	67	0.079	83	0.019	99	0.165	115	0.122
4	0.252	20	0.222	36	0.162	52	0.043	68	0.133	84	0.258	100	0.037	116	0.089
5	0.217	21	0.292	37	0.214	53	0.110	69	0.127	85	0.181	101	0.087	117	0.063
6	0.105	22	0.222	38	0.102	54	0.263	70	0.136	86	0.042	102	0.230	118	0.299
7	0.375	23	0.214	39	0.036	55	0.049	71	0.184	87	0.284	103	0.096	119	0.230
8	0.214	24	0.205	40	0.010	56	0.037	72	0.166	88	0.218	104	0.219	120	0.122
9	0.256	25	0.100	41	0.173	57	0.108	73	0.015	89	0.249	105	0.058	121	0.200
10	0.217	26	0.089	42	0.093	58	0.201	74	0.048	90	0.025	106	0.033	122	0.131
11	0.151	27	0.026	43	0.256	59	0.041	75	0.131	91	0.052	107	0.219	123	0.207
12	0.009	28	0.296	44	0.236	60	0.159	76	0.013	92	0.160	108	0.151	124	0.272
13	0.077	29	0.065	45	0.038	61	0.053	77	0.207	93	0.121	109	0.005	125	0.001
14	0.026	30	0.019	46	0.186	62	0.186	78	0.019	94	0.234	110	0.110	126	0.115
15	0.400	31	0.425	47	0.078	63	0.450	79	0.149	95	0.165	111	0.214	127	0.475

Figure C.4: This is the set of strain transmission parameter values β_j , j = 0, ..., 127 used in our 128 strain simulation. Note strains 0, 1, 3, 7, 15, 63, 127 (light blue cells) are part of a dominating sequence of values increasing steadily in steps of 0.025 from $\beta_0 = 0.30$ to $\beta_{127} = 0.475$ along the one-step-neighborhood pathway represented by the allele structures (0,0,0,0,0,0), (0,0,0,0,0,1), (0,0,0,0,0,1,1),...,(1,1,1,1,1,1,1). All the remaining β values were generated at random on the interval [0,0.3].

Getz et al., June 7, 2021




Figure C.5: This is a baseline 3-year no vaccination run for our 128-strain vaccination study with strain-specific transmission values depicted in Fig. C.4 and other parameter values as indicated on the dashboard (also see Table 1). See Fig. 6 in main text for enlarged plots of predominant strains.

Getz et al., June 7, 2021




Figure C.6: This is vaccination in years 2 and 3 against strain 0 at the rate of 0.2% of the population per day in our 128-strain vaccination study with strain-specific transmission values depicted in Fig. C.4 and other parameter values as indicated on the dashboard (also see Table 1). See Fig. 6 in main text for enlarged plots of predominant strains.

Getz et al., June 7, 2021




Figure C.7: This is vaccination in years 2 and 3 against strain 127 at the rate of 0.2% of the population per day in our 128-strain vaccination study with strain-specific transmission values depicted in Fig. C.4 and other parameter values as indicated on the dashboard (also see Table 1). See Fig. 6 in main text for enlarged plots of predominant strains.

Getz et al., June 7, 2021




Figure C.8: This is a multivalent vaccination in years 2 and 3 against strains 0, 7, 31 and 127 at the rate of 1.0% of the population per day in our 128-strain vaccination study with strain-specific transmission values depicted in Fig. C.4 and other parameter values as indicated on the dashboard (also see Table 1), except that the cross immunity matrix **C** is now defined by Eq. A.7. See Fig. 6 in main text for enlarged plots of predominant strains.

Getz et al., June 7, 2021




Figure C.9: This is a bivalent vaccination in years 2 and 3 against strains 0 and 127 at the rate of 0.2% of the population per day in our 128-strain vaccination study with strain-specific transmission values depicted in Fig. C.4 and other parameter values as indicated on the dashboard (also see Table 1), except that the half-wining values has been increased fivefold $t^{\text{half}} = 1825$ days the cross immunity matrix **C** is now defined by Eq. A.7 with c = 0.9. See Fig. 6 in main text for enlarged plots of the predominant strain 0.